slno-10q_20200331.htm

0001564590-20-024654.txt : 20200512 0001564590-20-024654.hdr.sgml : 20200512 20200512160657 ACCESSION NUMBER: 0001564590-20-024654 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200512 DATE AS OF CHANGE: 20200512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 20869131 BUSINESS ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 10-Q 1 slno-10q_20200331.htm 10-Q slno-10q_20200331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36593

SOLENO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

77-0523891

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

203 Redwood Shores Parkway, Suite 500

Redwood City, California

(Address of principal executive offices)

94065

(Zip Code)

(650) 213-8444

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	SLNO	NASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 8, 2020, there were 44,710,790 shares of the registrant’s Common Stock, par value $0.001 per share, outstanding.

SOLENO THERAPEUTICS, INC.

TABLE OF CONTENTS

	Page
PART I—FINANCIAL INFORMATION	3
Item 1. Financial Statements	3
Condensed Consolidated Balance Sheets	3
Condensed Consolidated Statements of Operations (unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)	5
Condensed Consolidated Statements of Cash Flows (unaudited)	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3. Quantitative and Qualitative Disclosures About Market Risk	20
Item 4. Controls and Procedures	20
PART II—OTHER INFORMATION	21
Item 1. Legal Proceedings	21
Item 1A. Risk Factors	21
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3. Defaults Upon Senior Securities	22
Item 4. Mine Safety Disclosures	22
Item 5. Other Information	22
Item 6. Exhibits	22
EXHIBIT INDEX	23
SIGNATURES	24

PART I—FINANCIAL INFORMATION

Item 1.

Financial Statements

Soleno Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands except share and per share data)

	March 31, 2020			December 31, 2019
Assets	(Unaudited)
Current assets
Cash and cash equivalents	$	15,070		$	20,733
Prepaid expenses and other current assets		572			411
Total current assets		15,642			21,144
Long-term assets
Property and equipment, net		19			22
Operating lease right-of-use assets		332			398
Finance lease right-of-use assets		22			24
Intangible assets, net		16,039			16,525
Other long-term assets		59			59
Total assets	$	32,113		$	38,172
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	3,480		$	1,995
Accrued compensation		338			283
Accrued clinical trial site costs		2,846			1,999
Operating lease liabilities		315			305
Other current liabilities		308			382
Total current liabilities		7,287			4,964
Long-term liabilities
2017 PIPE Warrant liability		7,656			10,822
2018 PIPE Warrant liability		1,107			1,354
Contingent liability for Essentialis purchase price		6,522			5,938
Other long-term liabilities		60			147
Total liabilities		22,632			23,225
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 100,000,000 shares authorized, 44,686,811 and 44,658,054 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively.		45			45
Additional paid-in-capital		173,100			172,708
Accumulated deficit		(163,664	)		(157,806	)
Total stockholders’ equity		9,481			14,947
Total liabilities and stockholders’ equity	$	32,113		$	38,172

See accompanying notes to condensed consolidated financial statements

Soleno Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(In thousands except share and per share data)

	Three Months Ended March 31,
	2020			2019
Operating expenses
Research and development	$	6,695		$	2,760
General and administrative		2,003			2,012
Change in fair value of contingent consideration		584			206
Total operating expenses		9,282			4,978
Operating loss		(9,282	)		(4,978	)
Other income (expense)
Change in fair value of warrants liabilities		3,413			(1,919	)
Loss from minority interest investment		—			(190	)
Interest income		11			57
Total other income (expense)		3,424			(2,052	)
Net loss	$	(5,858	)	$	(7,030	)
Net loss per common share, basic and diluted	$	(0.13	)	$	(0.22	)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share		44,679,858			31,756,120

See accompanying notes to condensed consolidated financial statements

Soleno Therapeutics, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

For the Three Months Ended March 31, 2020 and 2019

(unaudited)

(In thousands except share data)

	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity
Balances at January 1, 2020		44,658,054	$	45	$	172,708	$	(157,806	)	$	14,947
Stock-based compensation						296					296
Issuance of restricted stock units under equity incentive plans		28,757		—		96					96
Net loss								(5,858	)		(5,858	)
Balances at March 31, 2020		44,686,811	$	45	$	173,100	$	(163,664	)	$	9,481




	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity
Balances at January 1, 2019		31,755,169	$	32	$	157,413	$	(127,032	)	$	30,413
Stock-based compensation						202					202
Issuance of restricted stock units under equity incentive plans		21,415		—		46					46
Net loss								(7,030	)		(7,030	)
Balances at March 31, 2019		31,776,584	$	32	$	157,661	$	(134,062	)	$	23,631

See accompanying notes to condensed consolidated financial statements

Soleno Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(In thousands)

	Three Months Ended March 31,
	2020			2019
Cash flows from operating activities:
Net loss	$	(5,858	)	$	(7,030	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		489			489
Noncash lease expense		68			110
Stock-based compensation expense		392			248
Change in fair value of stock warrants		(3,413	)		1,919
Change in fair value of contingent consideration		584			206
Operating loss on minority interest investment		—			190
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets		(161	)		(74	)
Due from related party		—			(8	)
Accounts payable		1,485			324
Accrued compensation		55			(92	)
Accrued clinical trial site costs		847			188
Operating lease liabilities		10			(117	)
Other liabilities		(157	)		(40	)
Net cash used in operating activities		(5,659	)		(3,687	)
Cash flows from investing activities:
Purchases of property and equipment		—			(10	)
Net cash used in investing activities		—			(10	)
Cash flows from financing activities:
Principal paid on finance lease liabilities		(4	)		—
Net cash used in financing activities		(4	)		—
Net decrease in cash and cash equivalents		(5,663	)		(3,697	)
Cash and cash equivalents, beginning of period		20,733			23,099
Cash and cash equivalents, end of period	$	15,070		$	19,402

See accompanying notes to condensed consolidated financial statements.

Soleno Therapeutics, Inc.

March 31, 2020

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1. Overview

Soleno Therapeutics, Inc. (the “Company” or “Soleno”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company initially established its operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs. During 2017, Soleno received stockholder approval to amend its Amended and Restated Certificate of Incorporation to change its name from “Capnia, Inc.” to “Soleno Therapeutics, Inc.” and merged with Essentialis, Inc. After the merger, the Company’s primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and the Company divested itself of its prior business efforts.

The Company’s lead candidate is Diazoxide Choline Controlled Release tablets, or DCCR, once-daily oral tablets for the treatment of Prader-Willi Syndrome, or PWS. DCCR is currently being evaluated in a Phase III clinical development program. The Phase III study (C601 or DESTINY PWS), a 3-month randomized, double-blind placebo-controlled study, completed enrollment in January 2020 with 127 patients at 29 sites in the US and UK. Patients who complete treatment in DESTINY PWS are eligible to receive DCCR for up to 36 months in C602, an open-label extension study. Top line results from DESTINY PWS are expected in 1H2020. DCCR has orphan designation for the treatment of PWS in the United States, or U.S., as well as in the European Union, or E.U.

Note 2. Going Concern and Management’s Plans

The Company had a net loss of $5.9 million during the three months ended March 31, 2020 and has an accumulated deficit of $163.7 million at March 31, 2020 resulting from having incurred losses since its inception. The Company had $15.1 million of cash on hand at March 31, 2020 and used $5.7 million of cash in its operating activities during the three months ended March 31, 2020. The Company has financed its operations principally through issuances of equity securities.

The accompanying condensed consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

The Company expects to continue incurring losses for the foreseeable future and will be required to raise additional capital to complete its clinical trials, pursue product development initiatives and penetrate markets for the sale of its products. Management believes that the Company will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but the Company’s access to such capital resources is uncertain and is not assured. If the Company is unable to secure additional capital, it may be required to curtail its clinical trials and development of new products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s efforts to complete its clinical trials and commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should it be unable to continue as a going concern.

Management believes that the Company does not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing. Additionally, in view of the Company’s expectation to incur significant losses for the foreseeable future it will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company’s access to such resources is not assured. Accordingly, management believes that there is substantial doubt regarding the Company’s ability to continue operating as a going concern within one year from the date of filing these financial statements.

Note 3. Summary of Significant Accounting Policies

There have been no material changes to the significant accounting policies during the three months ended March 31, 2020 as compared to the significant accounting policies described in Note 3 of the “Notes to Consolidated Financial Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. Below are those policies with current period updates.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2020, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2020. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2019, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 4, 2020.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, value and life of acquired intangibles, and the valuation of contingent liabilities. The contingent liability represents the fair value of the contingent consideration arising from the Company’s acquisition of Essentialis in 2017. As part of the purchase price, the Company is obligated to make cash earn out payments to Essentialis stockholders up to a maximum of $30 million upon the achievement of certain commercial milestones.

Recent Accounting Standards

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date.

Recently Adopted Accounting Standards

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement”. The ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company has adopted this ASU at the beginning of 2020. The adoption did not have a material impact on the Company’s condensed consolidated financial statements disclosures.

Recently Issued Accounting Standards

In December 2019, the FASB issued ASU 2019-12: “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this Update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company has not yet assessed the potential impact of adopting ASU 2019-12 on its condensed consolidated financial statements.

During the three months ended March 31, 2020, other than ASU 2019-12, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated interim financial statements.

Note 4. Fair Value of Financial Instruments

The carrying value of the Company’s cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items.

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the

measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

•

Level I — Unadjusted quoted prices in active markets for identical assets or liabilities;

•

Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

•

Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).

	Fair Value Measurements at March 31, 2020
	Total		Level 1		Level 2		Level 3
Liabilities
2017 PIPE warrant liability	$	7,656	$	—	$	—	$	7,656
2018 PIPE warrant liability		1,107		—		—		1,107
Essentialis purchase price contingency liability		6,522		—		—		6,522
Total common stock warrant and contingent consideration liability	$	15,285	$	—	$	—	$	15,285

	Fair Value Measurements at December 31, 2019
	Total		Level 1		Level 2		Level 3
Liabilities
2017 PIPE warrant liability	$	10,822	$	—	$	—	$	10,822
2018 PIPE warrant liability		1,354		—		—		1,354
Essentialis purchase price contingency liability		5,938		—		—		5,938
Total common stock warrant and contingent consideration liability	$	18,114	$	—	$	—	$	18,114

The Company’s estimated fair value of the 2017 PIPE Warrants and the 2018 PIPE Warrants was calculated using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation-pricing model requires the input of highly subjective assumptions including the expected stock price volatility, the expected term, the expected dividend yield and the risk-free interest rate. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Company’s analysis of the likelihood of obtaining specified approvals from the Federal Drug Administration as well as reaching cumulative revenue milestones. The Level 3 estimates are based, in part, on subjective assumptions.

During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. There were no transfers between levels within the hierarchy during the periods presented.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities (dollars in thousands).

	Series C Warrants					2017 PIPE Warrants					2018 PIPE Warrants					Purchase Price
	Number of Warrants			Liability		Number of Warrants		Liability			Number of Warrants		Liability			Contingent Liability
Balance at December 31, 2019		118,083		$	—		6,024,425	$	10,822			513,617	$	1,354		$	5,938
Expiration of Series C Warrants		(118,083	)		—		—		—			—		—			—
Change in value of 2017 PIPE Warrants		—			—		—		(3,166	)		—		—			—
Change in value of 2018 PIPE Warrants		—			—		—		—			—		(247	)		—
Change in value of contingent liability		—			—		—		—			—		—			584
Balance at March 31, 2020		—		$	—		6,024,425	$	7,656			513,617	$	1,107		$	6,522

Note 5. Warrant Liabilities

The Company has issued multiple warrant series, of which the 2017 PIPE Warrants and the 2018 PIPE Warrants (the “Warrants”) remain outstanding at March 31, 2020 and are considered liabilities pursuant to the guidance established by ASC 815 Derivatives and Hedging.

Accounting Treatment

The Company accounts for the Warrants in accordance with the guidance in ASC 815. As indicated below, the Company may be obligated to settle Warrants in cash. The Company classified the Warrants as long-term liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s condensed consolidated statements of operations.

Series C Warrants

As of March 31, 2020, the fair value of the Series C Warrants was zero as the warrants had expired. This balance is consistent with the balance as of December 31, 2019.

The Company calculated the fair value of the Series C Warrants as of December 31, 2019 using a Black-Scholes pricing model. The Black-Scholes pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs.

	December 31, 2019
Volatility		90	%
Contractual term (years)		0.17
Expected dividend yield		—	%
Risk-free rate		1.52	%

Warrants Issued as Part of the Units in the 2017 PIPE Offering

The 2017 PIPE Warrants were issued on December 15, 2017 in the 2017 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2017 PIPE Offering, and entitle the holder of each of the 8,141,116 units to purchase 0.74 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2017 PIPE Warrants and terminating at the earlier of December 15, 2020 or 30 days following positive Phase III results for the DCCR tablet in PWS.

The exercise price and number of shares of common stock issuable upon exercise of the 2017 PIPE Warrants may be adjusted in certain circumstances, including the event of a stock split, stock dividend, extraordinary dividend, or recapitalization, reorganization, merger or consolidation. However, the exercise price of the 2017 PIPE Warrants will not be reduced below $1.72.

In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology.

As of March 31, 2020, the fair value of the 2017 PIPE Warrants was estimated at $7.7 million. The decrease in the fair value of the liability for the 2017 PIPE Warrants of approximately $3.2 million during the three months ended March 31, 2020 was recorded as other income (expense) in the condensed consolidated statements of operations.

The Company has calculated the fair value of the 2017 PIPE Warrants using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The following summarizes certain key assumptions used in estimating the fair values.

	March 31, 2020			December 31, 2019
Volatility		105	%		99	%
Contractual term (years)		0.7			1.0
Expected dividend yield		—	%		—	%
Risk-free rate		0.10	%		1.60	%

Warrants Issued as Part of the Units in the 2018 PIPE Offering

The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and entitle the holders of each of the 10,272,375 units to purchase 0.05 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2018 PIPE Warrants and terminating on December 21, 2023.

The exercise price and number of shares of common stock issuable upon exercise of the 2018 PIPE Warrants may be adjusted in certain circumstances, including the event of a stock split, stock dividend, extraordinary dividend, or recapitalization, reorganization, merger or consolidation. However, the exercise price of the 2018 PIPE Warrants will not be reduced below $2.00.

As of March 31, 2020, the fair value of the 2018 PIPE Warrants was estimated at $1.1 million. The approximate $247,000 decrease in the fair value of the liability for the 2018 PIPE Warrants during the three months ended March 31, 2020 was recorded as other income (expense) in the condensed consolidated statements of operations.

The Company has calculated the fair value of the 2018 PIPE Warrants using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The following summarizes certain key assumptions used in estimating the fair values.

	March 31, 2020			December 31, 2019
Volatility		105	%		99	%
Contractual term (years)		3.7			4.0
Expected dividend yield		—	%		—	%
Risk-free rate		0.33	%		1.56	%

The Monte Carlo simulation of a geometric Brownian motion model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates.

•

Volatility: The Company calculates the estimated volatility rate based on the volatilities of common stock of comparable companies in its industry.

•

Contractual term: The expected life of the warrants, which is based on the contractual term of the warrants.

•

Expected dividend yield: The Company has never declared or paid any cash dividends and does not currently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.

•

Risk-free rate: The risk-free interest rate is based on the U.S. Treasury rate for similar periods as those of expected volatility.

Note 6. Commitments and Contingencies

Facility Leases

The Company’s previous operating lease for its headquarters facility office space in Redwood City, California, terminated in August 2019, along with the related subleases. One of the subleases was with Capnia, of which the Company was a joint owner until September 2019. Sublease income received from Capnia during the three months ended March 31, 2019 was approximately $25,000.

In July 2019, the Company executed a non-cancellable lease agreement for 6,368 square feet of new space in Redwood City, California, which began in September 2019 and expires in May 2021. The lease also provides the Company with the right to use office furniture in the space and allows the purchase of this furniture at the end of the lease term for $1. The lease agreement requires monthly lease payments of approximately $29,000 beginning in November of 2019, with an increase to approximately $30,000 per month in September of 2020. The Company has accounted for the new lease as an operating lease for the office space and a finance lease for the office furniture, based on their relative standalone prices.

The components of lease expense during the three months ended March 31, 2019 and 2018 were as follows (in thousands):

	Three Months Ended March 31,
	2020		2019
Operating lease cost:
Operating lease cost	$	76	$	119
Sublease income		—		(65	)
Total operating lease cost	$	76	$	54

Finance lease cost:
Amortization of right-of-use assets	$	2	$	—
Interest on lease liabilities		1		—
Total finance lease cost	$	3	$	—

Contingencies

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.

Note 7. CoSense Joint Venture Agreement and Discontinued Operations

In December 2017, the Company entered into a joint venture with OptAsia Healthcare Limited, or OAHL, with respect to its CoSense product by agreeing to sell shares of Capnia, its then wholly-owned subsidiary, to OAHL. CoSense was Soleno’s first Sensalyze Technology Platform product to receive 510(k) clearances from the FDA and CE Mark certification. The Company’s entry into the joint venture resulted from a comprehensive review of strategic alternatives for its legacy products and product candidates following its transition to a primarily therapeutic drug product company. The terms of the Joint Venture Agreement provided that OAHL would invest up to a total of $2.2 million in Capnia’s common shares on an incremental quarterly basis commencing in December 2017. OAHL was also responsible for funding a portion of the Capnia operations. The Joint Venture Agreement provided that Capnia would issue shares of common stock to OAHL based on a negotiated price of $1.00 per share when the cumulative investment made by OAHL equaled or exceeded $1.2 million. For financial reporting purposes, Capnia’s assets, liabilities and results of operations had historically been consolidated with those of the Company.

held a controlling interest in Capnia and resulted in the deconsolidation of Capnia’s financial statements from those of the Company. The remaining 47% investment in Capnia was classified as an equity method investment and was presented as a Minority interest investment in former subsidiary in the condensed consolidated balance sheet. The Company’s share of Capnia’s net losses during the three months ended March 31, 2019 are recorded in the condensed consolidated statements of operations in the line titled “Loss from minority interest investment”. During September 2019, the Company sold its remaining 47% investment in Capnia. Following the transaction, the Company has no interest remaining in Capnia and the previous joint venture agreement with OAHL has been terminated.

Note 8. Stockholders’ Equity

Equity Incentive Plans

The Company has adopted the 2014 Equity Incentive Plan, or the Plan. Under the Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance units or performance shares to employees, directors, advisors, and consultants. Options granted under the Plan may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees, including officers and directors.

The Board of Directors has the authority to determine to whom stock options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. The vesting period is normally monthly over a period of 4 years from the vesting date. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The terms and conditions governing restricted stock units is at the sole discretion of the Board. As of March 31, 2020, a total of 190,601 shares are available for future grant under the Plan.

The Company recognizes stock-based compensation expense related to options and restricted stock units granted to employees, directors and consultants. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements during any of the periods presented.

Stock-based compensation expense was recognized in the condensed consolidated statements of operations as follows (in thousands).

	Three Months Ended March 31,
	2020		2019
Research and development	$	99	$	41
General and administrative		293		207
Total	$	392	$	248

Stock Options

The Company granted options to purchase 464,000 of the Company’s common stock during the three months ended March 31, 2019. There were no options granted during the three months ended March 31, 2020. The fair value of each award granted during the three months ended March 31, 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions.

Expected life (years)		6.0-6.1
Risk-free interest rate		2.6%
Volatility		71%
Dividend rate		— %

The Black-Scholes option-pricing model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates:

•

Expected life: The expected life of stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. The Company does not believe it is able to rely on historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term for use

in estimating the fair value-based measurement of stock options. Therefore, it has opted to use the “simplified method” for estimating the expected term of options.

•

Risk-free interest rate: The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected time to liquidity.

•

Volatility: The estimated volatility rate based on the volatilities of common stock of comparable companies in the Company’s industry.

•

Dividend rate: The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.

The following table summarizes stock option transactions for the three months ended March 31, 2020 as issued under the 2014 Plan:

	Number of Options			Weighted- Average Exercise Price per		Weighted Average Remaining Contractual Term
	Outstanding			Share		(in years)
Balance at December 31, 2019		2,123,117		$	4.62		7.87
Options canceled/forfeited		(38,359	)	$	2.11
Balance at March 31, 2020		2,084,758		$	4.66		7.59
Options vested at March 31, 2020		1,220,423		$	6.65		7.01
Options vested and expected to vest at March 31, 2020		2,084,758		$	4.66		7.59

The weighted-average grant date fair value of options granted was and $1.08 per share for the three months ended March 31, 2019. At March 31, 2020 total unrecognized employee stock-based compensation related to stock options was approximately $919,000, which is expected to be recognized over the weighted-average remaining vesting period of 2.2 years. As of March 31, 2020, the outstanding stock options had an intrinsic value of approximately $883,000.

Restricted Stock Units

There were 687,257 and 21,415 restricted stock units granted by the Company during the three months ended March 31, 2020 and March 31, 2019, respectively, to employees and directors. The shares granted to directors were 100% vested on the grant date and represent compensation for past board services. The shares granted to employees typically vest annually over a period of four years. The shares were valued based on the Company’s common stock price on the grant date.

The following table summarizes restricted stock unit transactions for the three months ended March 31, 2020 as issued under the Plan:

	Number of Restricted Stock Units			Weighted- Average Grant-Date Fair Value per Share
Outstanding at December 31, 2019		-
Restricted stock units granted		687,257		$	3.83
Restricted stock units vested		(28,757	)	$	3.35
Outstanding at March 31, 2020		658,500		$	3.85

The weighted-average grant-date fair value of all restricted stock units granted during the three months ended March 31, 2020 and March 31, 2019 was $3.83 and $2.18, respectively. The fair value of all restricted stock units vested during the three months ended March 31, 2020 and March 31, 2019 was approximately $96,000 and approximately $46,000, respectively. At March 31, 2020 total unrecognized employee stock-based compensation related to restricted stock units was $2.4 million, which is expected to be recognized over the weighted-average remaining vesting period of 3.7 years.

2014 Employee Stock Purchase Plan

The Company’s board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan, or the ESPP. The ESPP has become effective, and the board of directors will implement commencement of offers thereunder in its discretion. A total of

27,967 shares of the Company’s common stock has been made available for sale under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that the board of directors authorizes commencement, equal to the least of:

•

1.0% of the outstanding shares of the Company’s common stock on the first day of such year;

•

55,936 shares; or

•

such amount as determined by the board of directors.

As of March 31, 2020, there were no purchases by employees under this plan.

Series D Warrants

The Company issued 270,270 Series D Warrants in October 2015, which are exercisable into 540,540 shares of the Company’s common stock, with an exercise price of $8.75 and a term of five years expiring on October 15, 2020. The Company’s Series D Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirements to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Series D Warrant agreement further provides for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Series D Warrant is convertible in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of this securities agreement and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the proceeds to the registration payment arrangement. The Series D Warrant agreement specifically provides that under no circumstances will the Company be required to settle any Series D Warrant exercise for cash, whether by net settlement or otherwise.

Accounting Treatment

The Company accounts for the Series D Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging. As indicated above, the Company is not required under any circumstance to settle any Series D Warrant exercise for cash. The Company has therefore classified the value of the Series D Warrants as permanent equity.

Other Common Stock Warrants

As of March 31, 2020, the Company had 102,070 common stock warrants outstanding from the 2010/2012 convertible notes, with an exercise price of $24.35 and a term of 10 years expiring in November 2024. The Company also had 16,500 common stock warrants issued to the underwriter in the Company’s IPO, with an exercise price of $35.70 and a term of 10 years, expiring in November 2024.

Note 9. Net loss per share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common stock actually outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding and dilutive potential common stock that would be issued upon the exercise of common stock warrants and options. For the three months ended March 31, 2020 and 2019, the effect of issuing the potential common stock is anti-dilutive due to the net losses in those periods and the number of shares used to compute basic and diluted earnings per share are the same in each of those periods.

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares).

	As of March 31,
	2020		2019
Warrants issued to 2010/2012 convertible note holders to purchase common stock		102,070		102,070
Options to purchase common stock		2,084,758		2,116,107
Outstanding restricted stock units		658,500		—
Warrants issued to underwriter to purchase common stock		16,500		16,500
Series A warrants to purchase common stock		—		485,121
Series C warrants to purchase common stock		—		118,083
Series D warrants to purchase common stock		540,540		540,540
2017 PIPE warrants		6,024,425		6,024,425
2018 PIPE warrants		513,617		513,617
Total		9,940,410		9,916,463

Note 10. Subsequent Events

The Company has evaluated its subsequent events from March 31, 2020 through the date these condensed consolidated financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated financial statements other than the item noted below.

PPP Term Note

On April 22, 2020, the Company entered into a $350,000 loan with Silicon Valley Bank (“SVB”) pursuant to the Small Business Administration’s (“SBA”) Paycheck Protection Program ("the PPP"). The loan proceeds were intended to be used for payroll, rent and utilities over the eight- week period following the date of the loan. At the time the Company applied for the PPP loan, it believed in good faith that it met all of the certification requirements for a PPP loan. However, on April 23, 2020, the SBA issued additional guidance with respect to PPP loans. The Company evaluated this new guidance and concluded that currently it may not be able to meet all of the certification requirements. As such, the Company decided to return all of the funds received under the PPP loan (including interest accrued on such funds) to the SBA and on May 6, 2020 the Company instructed SVB to make repayment.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

The interim consolidated financial statements included in this Quarterly Report on Form 10-Q and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2019, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Company’s Form 10-K for the year ended December 31, 2019. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are subject to risks and uncertainties, including those set forth in Part II – Other Information, Item 1A. Risk Factors below and elsewhere in this report that could cause actual results to differ materially from historical results or anticipated results.

Overview

We were incorporated in the State of Delaware on August 25, 1999, and are located in Redwood City, California. We initially established our operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs. During 2017, we received stockholder approval to amend our Amended and Restated Certificate of Incorporation to change our name from “Capnia, Inc.” to “Soleno Therapeutics, Inc.” and merge with Essentialis, Inc. After the merger, our primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and we divested our self of our prior business efforts.

Our lead candidate is Diazoxide Choline Controlled Release tablets, or DCCR, once-daily oral tablets for the treatment of Prader-Willi Syndrome, or PWS. DCCR is currently being evaluated in a Phase III clinical development program. The Phase III study (C601 or DESTINY PWS), a 3-month randomized, double-blind placebo-controlled study, completed enrollment in January 2020 with 127 patients at 29 sites in the US and UK. Patients who complete treatment in DESTINY PWS are eligible to receive DCCR for up to 36 months in C602, an open-label extension study. Top line results from DESTINY PWS are expected in 1H2020. DCCR has orphan designation for the treatment of PWS in the United States, or U.S., as well as in the European Union, or E.U.

The spread of the COVID-19 virus during the first quarter of 2020 has caused an economic downturn on a global scale, as well as significant volatility in the financial markets. In March 2020, the World Health Organization declared the spread of the COVID-19 virus a pandemic. Due to stay at home orders both in the United States and United Kingdom, we have instituted a work from home policy for all of our employees and other service providers to protect their health and well-being. We have ensured that all of our employees have essential materials to work comfortably and efficiently from home during this time.

We have not experienced a significant financial impact directly related to the pandemic. As of March 31, 2020, we have cash and cash equivalents of $15.1 million, however management believes that the Company does not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing. Additionally, in view of the Company’s expectation to incur significant losses for the foreseeable future it will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company’s access to such resources is not assured. We have not experienced a significant operational impact on our primary development program, DCCR for the treatment of PWS, and our ongoing clinical trial DESTINY PWS, although we cannot rule out future delays as authorities fight the spread of the virus. As of March 31, 2020, we had an accumulated deficit of $163.7 million, primarily as a result of research and development and general and administrative expenses. We may never be successful in commercializing our novel therapeutic-lead candidate DCCR. Accordingly, we expect to incur significant losses from operations for the foreseeable future, and there can be no assurance that we will ever generate significant revenue or profits.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. Our significant accounting policies are more fully described in Note 3 of our most recent Form 10-K.

Results of Operations

Comparison of the three months ended March 31, 2020 and 2019

	Three Months Ended March 31,						Increase (decrease)
	2020			2019			Amount			Percentage
	(in thousands)
Operating expenses
Research and development	$	6,695		$	2,760		$	3,935			143	%
General and administrative		2,003			2,012			(9	)		0	%
Change in fair value of contingent consideration		584			206			378			183	%
Total operating expenses		9,282			4,978			4,304			86	%
Operating loss		(9,282	)		(4,978	)		(4,304	)		86	%
Other income (expense)
Change in fair value of warrants liabilities		3,413			(1,919	)		5,332			278	%
Loss from minority interest investment		—			(190	)		190			100	%
Interest income		11			57			(46	)		81	%
Total other income (expense)		3,424			(2,052	)		5,476			267	%
Net loss	$	(5,858	)	$	(7,030	)	$	1,172			17	%

Revenue

We have yet not commenced commercialization of DCCR, our current sole product, and accordingly, through March 31, 2020, have generated no revenue from operations.

Research and development expense

Research and development expense of $6.7 million for the three months ended March 31, 2020 increased by $3.9 million over the three months ended March 31, 2019. In January 2020 we announced the completion of target enrollment in DESTINY III trial. As of March 31, 2020, we had 29 clinical trial sites initiated compared to 15 as of March 31, 2019. As a result, we have incurred increased clinical site costs, consulting costs and lab costs. In addition, we are increasing our investment in clinical manufacturing costs to supply DCCR to the patients in the trial and to prepare for the next phase in the regulatory approval process.

General and administrative expense

General and administrative expense of $2.0 million for the three months ended March 31, 2020 was generally consistent with the expense during the three months ended March 31, 2019.

Change in fair value of contingent consideration

We are obligated to make cash payments of up to a maximum of $30 million to Essentialis stockholders upon the achievement of certain future commercial milestones associated with the sale of Essentialis’ product in accordance with the terms of the Essentialis merger agreement. The fair value of the liability for the contingent consideration payable by us achieving the commercial sales milestones of $100 million and $200 million was estimated to be $6.5 million as of March 31, 2020, an approximate $584,000 increase from the estimate as of December 31, 2019. During the three months ended March 31, 2019 the estimate increased approximately $206,000 from the liability of $5.6 million estimated at December 31, 2018.

Other income (expense)

We had other income of $3.4 million in the three months ended March 31, 2020, compared to other expense of $1.9 million during the three months ended March 31, 2019. The change of $5.5 million was primarily due to a $3.4 million decrease in the fair value of our outstanding warrants during the three months ended March 31, 2020 compared to an increase of $1.9 million during the three months ended March 31, 2019. In addition, during the three months ended March 31, 2019 we recorded an approximate $190,000 loss from our minority interest investment in Capnia, our former subsidiary. These increases were slightly offset by approximately $46,000 less of interest income recorded during the three months ended March 31, 2020 compared to March 31, 2019.

Liquidity and Capital Resources

We had a net loss of $5.9 million during the three months ended March 31, 2020 and an accumulated deficit of $163.7 million at March 31, 2020 as a result of having incurred losses since our inception. We had $8.4 million of working capital at March 31, 2020 and used $5.7 million of cash in operating activities during the three months ended March 31, 2020. We have financed our operations principally through issuances of equity securities.

We expect to continue incurring losses for the foreseeable future and will be required to raise additional capital to complete our clinical trials, pursue product development initiatives and penetrate markets for the sale of our products. We believe that we will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but the access to such capital resources is uncertain and is not assured. If we are unable to secure additional capital, we may be required to curtail our clinical trials and development of new products and take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays in our efforts to complete clinical trials and commercialize our products, which is critical to the realization of our business plan and our future operations. These matters raise substantial doubt about our ability to continue as a going concern within one year from the date of filing this quarterly report.

The accompanying condensed consolidated financial statements have been prepared under the assumption we will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to our ability to continue as a going concern.

Cash flows

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below:

	Three Months Ended March 31,
	2020			2019
	(in thousands)
Net cash used in operating activities	$	(5,659	)	$	(3,687	)
Net cash used in investing activities		—			(10	)
Net cash used in financing activities		(4	)		—
Net decrease in cash and cash equivalents	$	(5,663	)	$	(3,697	)

Cash used in operating activities

During the three months ended March 31, 2020, operating activities used net cash of $5.7 million, which was primarily due to the net loss of $5.9 million, adding back the non-cash credit of $2.8 million for the decrease in the fair value of stock warrants and contingent consideration, less other non-cash expenses of approximately $489,000 for depreciation and amortization, approximately $392,000 of expenses paid with equity awards, and approximately $68,000 for non-cash lease expense. Additionally, the usage of cash during the three months ended March 31, 2020 was reduced by $2.1 million due to changes in operating assets and liabilities.

During the three months ended March 31, 2019, operating activities used net cash of $3.7 million, which was primarily due to the loss from continuing operations of $7.0 million, adjusted for non-cash expenses of approximately $489,000 for depreciation and amortization, approximately $248,000 of expenses paid with equity awards, approximately $110,000 for non-cash lease expense, $2.1 million for the change in fair value of stock warrants and contingent consideration, and an approximate $190,000 operating loss on minority interest investment. Additionally, the usage of cash during the three months ended March 31, 2019 was reduced by approximately $181,000 due to changes in operating assets and liabilities.

Cash used in investing activities

Minimal cash was used for investing activities in the three months ended March 31, 2019 for the costs of acquiring property and equipment.

Cash provided by financing activities

Minimal cash was used for financing activities in the three months ended March 31, 2020 which were related to payments made on our finance lease.

As of March 31, 2020, we had cash and cash equivalents of $15.1 million.

We believe that we do not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing. We expect to continue incurring losses for the foreseeable future and will be required to raise additional capital to pursue our therapeutic product development initiatives. These conditions raise substantial doubt about our ability to continue as a going concern for a period of one year from the date of this report.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

There have not been any material changes to our exposure to market risk during the three months ended March 31, 2020. For additional information regarding market risk, refer to the Qualitative and Quantitative Disclosures About Market Risk section of the Form 10-K.

Item 4.

Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in U.S. Securities and Exchange Commission, or SEC, rules and forms, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective.

(b) Changes in Internal Control over Financial Reporting

There have been no changes to our internal control over financial reporting that occurred during the first fiscal quarter ended March 31, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, even if determined effective and no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives to prevent or detect misstatements. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

We may, from time to time, be party to litigation and subject to claims that arise in the ordinary course of business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We currently believe that these ordinary course matters will not have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Item 1A.

Risk Factors

An investment in our securities has a high degree of risk. Before you invest you should carefully consider the risks and uncertainties. A description of factors that could materially affect our business, financial condition, or operating results is included under “Risk Factors” in Item 1A of Part I of our 2019 Annual Report on Form 10-K and is incorporated herein by reference. Other than as noted below, there have been no material changes to the risk factor disclosure since our 2019 Annual Report on Form 10-K. The risk factors described in our Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial conditions and/or operating results. If any of these risks actually occur, our business, operating results and financial condition could be harmed, and the value of our stock could go down. This means you could lose all or a part of your investment.

Public health epidemics, pandemics or outbreaks, including the recent novel coronavirus pandemic (COVID-19), could adversely affect our business.

In December 2019, the novel coronavirus (“COVID-19”) was identified in Wuhan, China. The virus continues to spread globally, has been declared a pandemic by the World Health Organization and has spread to over 100 countries, including the United States. The COVID-19 outbreak is significantly affecting our employees, patients, communities and business operations, as well as the U.S. economy and financial markets. The full extent to which the COVID-19 outbreak will impact our business, results of operations, financial condition and cash flows will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets. As the COVID-19 pandemic continues, our results of operations, financial condition and cash flows are likely to be materially adversely affected, particularly if the pandemic persists for a significant amount of time.

COVID-19 or other public health epidemics, pandemics or outbreaks, and the resulting business or economic disruptions resulting therefrom, may adversely impact our business as well as our ability to raise capital. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will likely continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world.

While we cannot presently predict the scope and severity of any potential business shutdowns or disruptions, if we or any of our business partners, clinical trial sites, manufacturing sites and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. For example, if our Phase III clinical trial of DCCR for the treatment of PWS were to be delayed, it may have a material adverse effect on our business, results of operations, and financial condition. While there has been no meaningful impact on the timelines for top line data for the Phase III program, there have been certain changes in the conduct of our clinical trials depending on institution-, state- and country-specific restrictions such as stay at home requirements. The changes are consistent with the FDA’s and MHRA’s guidance regarding the conduct of clinical trials during the COVID-19 public health emergency. However, the changes in the way the trial is being conducted may impact the quality of the overall data being collected which may have implications for our future plans.

Several measures are currently being implemented by the United States and other governments to address the current COVID-19 pandemic and its economic impacts. At this time, it is impossible to predict the success of these measures and whether or not they will have unforeseen negative consequences for our business. In addition, our results of operations, financial position and cash flows may be adversely affected by federal or state laws, regulations, orders, or other governmental or regulatory actions addressing the current COVID-19 pandemic or the U.S. healthcare system, which, if adopted, could result in direct or indirect restrictions to our business, results of operations, financial condition and cash flow. For example, the State of California issued Executive Order N-33-20 on March 4, 2020 (the “Executive Order”), which proclaimed a State of Emergency to exist in California as a result of the threat of COVID-19. The Executive Order mandated that all our employees work from home and not come into our corporate offices in Redwood City, California. We currently do not know when and how such regulations may be eased.

The foregoing and other continued disruptions to our business as a result of COVID-19 could result in a material adverse effect on our business, results of operations, financial condition and cash flows. Furthermore, the COVID-19 pandemic could heighten the risks in certain of the other risk factors described herein.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form 10-Q, which Exhibit Index is incorporated herein by reference.

EXHIBIT INDEX

		Incorporated by Reference from
Exhibit Number	Description of Document	Registrant’s Form	Date Filed with the SEC	Exhibit Number	Filed Herewith

31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934, as amended				X

31.2	Certification of Principal Financial and Accounting Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934, as amended				X

32.1	Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X

32.2	Certification of Principal Financial and Accounting Officer Required Under Rule 13a-14(b) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X

101.INS	XBRL Instance Document.				X

101.SCH	XBRL Taxonomy Extension Schema Document.				X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.				X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.				X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document.				X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.				X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 12, 2020	SOLENO THERAPEUTICS, INC.

	By:	/s/ James Mackaness
		James Mackaness Chief Financial Officer (authorized officer and principal financial and accounting officer)

EX-31.1 2 slno-ex311_6.htm EX-31.1 slno-ex311_6.htm

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Anish Bhatnagar, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Soleno Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2020

/s/ Anish Bhatnagar

Anish Bhatnagar

President, Chief Executive Officer

(principal executive officer)

EX-31.2 3 slno-ex312_7.htm EX-31.2 slno-ex312_7.htm

Exhibit 31.2

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, James Mackaness, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Soleno Therapeutics, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2020

/s/ James Mackaness

James Mackaness

Chief Financial Officer

(principal financial and accounting officer)

EX-32.1 4 slno-ex321_8.htm EX-32.1 slno-ex321_8.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Soleno Therapeutics, Inc. (the “Company”) on Form 10-Q for the fiscal quarter March 31, 2020, as filed with the Securities and Exchange Commission (the “Report”), Anish Bhatnagar, President, Chief Executive Officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2020

/s/ Anish Bhatnagar

Anish Bhatnagar

President, Chief Executive Officer

(principal executive officer)

EX-32.2 5 slno-ex322_9.htm EX-32.2 slno-ex322_9.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Soleno Therapeutics, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended March 31, 2020, as filed with the Securities and Exchange Commission (the “Report”), James Mackaness, Chief Financial Officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2020

/s/ James Mackaness

James Mackaness

Chief Financial Officer

(principal financial and accounting officer)

EX-101.INS 6 slno-20200331.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:sqft 0001484565 2020-01-01 2020-03-31 0001484565 2020-05-08 0001484565 2020-03-31 0001484565 2019-12-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-03-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2020-03-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2019-12-31 0001484565 2019-01-01 2019-03-31 0001484565 us-gaap:CommonStockMember 2019-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001484565 us-gaap:RetainedEarningsMember 2019-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001484565 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001484565 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001484565 us-gaap:CommonStockMember 2020-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001484565 us-gaap:RetainedEarningsMember 2020-03-31 0001484565 us-gaap:CommonStockMember 2018-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001484565 us-gaap:RetainedEarningsMember 2018-12-31 0001484565 2018-12-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001484565 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001484565 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001484565 us-gaap:CommonStockMember 2019-03-31 0001484565 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001484565 us-gaap:RetainedEarningsMember 2019-03-31 0001484565 2019-03-31 0001484565 slno:SeriesCWarrantsMember 2020-01-01 2020-03-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-01-01 2020-03-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2020-01-01 2020-03-31 0001484565 slno:EssentialisIncMember slno:EarnoutPaymentsMember 2020-03-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-03-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-03-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2020-03-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2020-03-31 0001484565 slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001484565 us-gaap:FairValueInputsLevel3Member slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-12-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-12-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2019-12-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2019-12-31 0001484565 slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001484565 us-gaap:FairValueInputsLevel3Member slno:EssentialisIncMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001484565 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001484565 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001484565 slno:SeriesCWarrantsMember slno:CommonStockWarrantLiabilityMember 2019-12-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2019-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2019-12-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2019-12-31 0001484565 slno:SeriesCWarrantsMember slno:CommonStockWarrantLiabilityMember 2020-01-01 2020-03-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2020-01-01 2020-03-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2020-01-01 2020-03-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2020-01-01 2020-03-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2020-03-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember slno:CommonStockWarrantLiabilityMember 2020-03-31 0001484565 slno:PurchasePriceContingentLiabilityMember 2020-03-31 0001484565 slno:SeriesCWarrantsMember 2020-03-31 0001484565 slno:SeriesCWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001484565 slno:SeriesCWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001484565 slno:SeriesCWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2017-12-15 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityToPurchaseCommonStockMember srt:MinimumMember 2020-03-31 0001484565 us-gaap:MeasurementInputPriceVolatilityMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-03-31 0001484565 us-gaap:MeasurementInputPriceVolatilityMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-12-31 0001484565 us-gaap:MeasurementInputExpectedTermMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-03-31 0001484565 us-gaap:MeasurementInputExpectedTermMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-12-31 0001484565 us-gaap:MeasurementInputRiskFreeInterestRateMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2020-03-31 0001484565 us-gaap:MeasurementInputRiskFreeInterestRateMember slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-12-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2018-12-19 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember srt:MinimumMember 2020-03-31 0001484565 us-gaap:MeasurementInputPriceVolatilityMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2020-03-31 0001484565 us-gaap:MeasurementInputPriceVolatilityMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2019-12-31 0001484565 us-gaap:MeasurementInputExpectedTermMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2020-03-31 0001484565 us-gaap:MeasurementInputExpectedTermMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2019-12-31 0001484565 us-gaap:MeasurementInputRiskFreeInterestRateMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2020-03-31 0001484565 us-gaap:MeasurementInputRiskFreeInterestRateMember slno:TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember 2019-12-31 0001484565 us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001484565 slno:CapniaIncJointVentureMember stpr:CA 2019-01-01 2019-03-31 0001484565 stpr:CA 2019-07-31 0001484565 stpr:CA 2020-01-01 2020-03-31 0001484565 stpr:CA 2019-07-01 2019-07-31 0001484565 stpr:CA 2019-11-01 2019-11-30 0001484565 srt:ScenarioForecastMember stpr:CA 2020-09-01 2020-09-30 0001484565 slno:OAHLMember slno:CapniaIncJointVentureMember us-gaap:CorporateJointVentureMember 2017-12-31 0001484565 slno:OAHLMember slno:CapniaIncJointVentureMember us-gaap:CorporateJointVentureMember 2018-09-30 0001484565 slno:OAHLMember slno:CapniaIncJointVentureMember us-gaap:CorporateJointVentureMember 2018-10-16 2018-10-16 0001484565 slno:CapniaIncJointVentureMember 2018-07-01 2018-09-30 0001484565 slno:CapniaIncJointVentureMember 2019-09-01 2019-09-30 0001484565 slno:OAHLMember slno:CapniaIncJointVentureMember 2019-09-30 0001484565 srt:MinimumMember 2020-03-31 0001484565 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-01-01 2020-03-31 0001484565 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001484565 slno:IncentiveStockOptionsMember srt:MaximumMember 2020-01-01 2020-03-31 0001484565 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-03-31 0001484565 us-gaap:EmployeeStockOptionMember 2020-03-31 0001484565 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0001484565 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0001484565 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0001484565 us-gaap:SegmentContinuingOperationsMember 2020-01-01 2020-03-31 0001484565 us-gaap:SegmentContinuingOperationsMember 2019-01-01 2019-03-31 0001484565 srt:MinimumMember 2019-01-01 2019-03-31 0001484565 srt:MaximumMember 2019-01-01 2019-03-31 0001484565 us-gaap:EmployeeStockOptionMember 2019-12-31 0001484565 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0001484565 us-gaap:EmployeeStockMember 2020-03-31 0001484565 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0001484565 slno:SeriesDWarrantsMember 2015-10-31 0001484565 slno:SeriesDWarrantsMember 2015-10-01 2015-10-31 0001484565 slno:WarrantsToPurchaseCommonStockMember slno:TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember 2020-03-31 0001484565 slno:WarrantsToPurchaseCommonStockMember slno:TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember 2020-01-01 2020-03-31 0001484565 slno:UnderwriterMember 2020-03-31 0001484565 slno:UnderwriterMember 2020-01-01 2020-03-31 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-03-31 0001484565 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-03-31 0001484565 us-gaap:StockOptionMember 2020-01-01 2020-03-31 0001484565 us-gaap:StockOptionMember 2019-01-01 2019-03-31 0001484565 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001484565 slno:UnderwriterMember 2019-01-01 2019-03-31 0001484565 slno:SeriesAWarrantsToPurchaseCommonStockMember 2019-01-01 2019-03-31 0001484565 slno:SeriesCWarrantsToPurchaseCommonStockMember 2019-01-01 2019-03-31 0001484565 slno:SeriesDWarrantsToPurchaseCommonStockMember 2020-01-01 2020-03-31 0001484565 slno:SeriesDWarrantsToPurchaseCommonStockMember 2019-01-01 2019-03-31 0001484565 slno:TwoThousandSeventeenPIPEWarrantLiabilityMember 2019-01-01 2019-03-31 0001484565 slno:TwoThousandEighteenPIPEWarrantLiabilityMember 2019-01-01 2019-03-31 0001484565 slno:SiliconValleyBankMember slno:PaycheckProtectionProgramTermNoteMember us-gaap:SubsequentEventMember 2020-04-22 10-Q false 2020-03-31 2020 Q1 SOLENO THERAPEUTICS INC 0001484565 --12-31 Non-accelerated Filer true false 44710790 001-36593 77-0523891 203 Redwood Shores Parkway Suite 500 Redwood City CA 94065 650 213-8444 DE true false Yes Yes false Common Stock, $0.001 par value SLNO NASDAQ

15070000

20733000

572000

411000

15642000

21144000

19000

22000

332000

398000

22000

24000

16039000

16525000

59000

32113000

38172000

3480000

1995000

338000

283000

2846000 1999000

315000

305000

308000

382000

7287000

4964000

7656000

10822000

1107000

1354000

6522000 5938000

60000

147000

22632000

23225000

45000

173100000

172708000

-163664000

-157806000

9481000

14947000

32113000

38172000

0.001

100000000

44686811

44658054

44686811

44658054

6695000

2760000

2003000

2012000

584000 206000

9282000

4978000

-9282000

-4978000

-3413000

1919000

-190000

11000

57000

3424000

-2052000

-5858000

-7030000

-0.13

-0.22

44679858

31756120

44658054

45000

172708000

-157806000

296000

28757

96000

-5858000

44686811

45000

173100000

-163664000

31755169

32000

157413000

-127032000

30413000

202000

21415

46000

-7030000

31776584

32000

157661000

-134062000

23631000

-5858000

-7030000

489000

68000 110000

392000

248000

-190000

161000

74000

8000

1485000

324000

55000

-92000

847000 188000 10000 -117000

-157000

-40000

-5659000

-3687000

10000

-10000

4000

-4000

-5663000

-3697000

20733000

23099000

15070000

19402000

Note 1. Overview <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soleno Therapeutics, Inc. (the “Company” or “Soleno”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company initially established its operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs.  During 2017, Soleno received stockholder approval to amend its Amended and Restated Certificate of Incorporation to change its name from “Capnia, Inc.” to “Soleno Therapeutics, Inc.” and merged with Essentialis, Inc. After the merger, the Company’s primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and the Company divested itself of its prior business efforts. <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5%;color:#000000;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s lead candidate is Diazoxide Choline Controlled Release tablets, or DCCR,  once-daily oral tablets for the treatment of Prader-Willi Syndrome, or PWS. DCCR is currently being evaluated in a Phase III clinical development program. The Phase III study (C601 or DESTINY PWS), a 3-month randomized, double-blind placebo-controlled study, completed enrollment in January 2020 with 127 patients at 29 sites in the US and UK. Patients who complete treatment in DESTINY PWS are eligible to receive DCCR for up to 36 months in C602, an open-label extension study. Top line results from DESTINY PWS are expected in 1H2020. DCCR has orphan designation for the treatment of PWS in the United States, or U.S., as well as in the European Union, or E.U.

Note 4. Fair Value of Financial Instruments The carrying value of the Company’s cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Level I — Unadjusted quoted prices in active markets for identical assets or liabilities; </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. </td></tr></table></div> The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE warrant liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Essentialis purchase price contingency liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock warrant and contingent <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   consideration liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,285</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,285</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE warrant liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Essentialis purchase price contingency liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock warrant and contingent <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   consideration liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div></div>   The Company’s estimated fair value of the 2017 PIPE Warrants and the 2018 PIPE Warrants was calculated using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation-pricing model requires the input of highly subjective assumptions including the expected stock price volatility, the expected term, the expected dividend yield and the risk-free interest rate. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Company’s analysis of the likelihood of obtaining specified approvals from the Federal Drug Administration as well as reaching cumulative revenue milestones. The Level 3 estimates are based, in part, on subjective assumptions. During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. There were no transfers between levels within the hierarchy during the periods presented. The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities (dollars in thousands). <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contingent <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,083</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,024,425</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,617</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiration of Series C Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,083</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of 2017 PIPE Warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,166</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of 2018 PIPE Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of contingent liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,024,425</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,617</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>  </div>

Note 5. Warrant Liabilities The Company has issued multiple warrant series, of which the 2017 PIPE Warrants and the 2018 PIPE Warrants (the “Warrants”) remain outstanding at March 31, 2020 and are considered liabilities pursuant to the guidance established by ASC 815 Derivatives and Hedging. Accounting Treatment The Company accounts for the Warrants in accordance with the guidance in ASC 815. As indicated below, the Company may be obligated to settle Warrants in cash. The Company classified the Warrants as long-term liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s condensed consolidated statements of operations. Series C Warrants As of March 31, 2020, the fair value of the Series C Warrants was zero as the warrants had expired. This balance is consistent with the balance as of December 31, 2019. The Company calculated the fair value of the Series C Warrants as of December 31, 2019 using a Black-Scholes pricing model. The Black-Scholes pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div> Warrants Issued as Part of the Units in the 2017 PIPE Offering The 2017 PIPE Warrants were issued on December 15, 2017 in the 2017 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2017 PIPE Offering, and entitle the holder of each of the 8,141,116 units to purchase 0.74 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2017 PIPE Warrants and terminating at the earlier of December 15, 2020 or 30 days following positive Phase III results for the DCCR tablet in PWS. The exercise price and number of shares of common stock issuable upon exercise of the 2017 PIPE Warrants may be adjusted in certain circumstances, including the event of a stock split, stock dividend, extraordinary dividend, or recapitalization, reorganization, merger or consolidation. However, the exercise price of the 2017 PIPE Warrants will not be reduced below $1.72. In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology. As of March 31, 2020, the fair value of the 2017 PIPE Warrants was estimated at $7.7 million. The decrease in the fair value of the liability for the 2017 PIPE Warrants of approximately $3.2 million during the three months ended March 31, 2020 was recorded as other income (expense) in the condensed consolidated statements of operations.  The Company has calculated the fair value of the 2017 PIPE Warrants using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The following summarizes certain key assumptions used in estimating the fair values.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div> Warrants Issued as Part of the Units in the 2018 PIPE Offering The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and entitle the holders of each of the 10,272,375 units to purchase 0.05 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2018 PIPE Warrants and terminating on December 21, 2023.   The exercise price and number of shares of common stock issuable upon exercise of the 2018 PIPE Warrants may be adjusted in certain circumstances, including the event of a stock split, stock dividend, extraordinary dividend, or recapitalization, reorganization, merger or consolidation. However, the exercise price of the 2018 PIPE Warrants will not be reduced below $2.00. In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology. As of March 31, 2020, the fair value of the 2018 PIPE Warrants was estimated at $1.1 million. The approximate $247,000 decrease in the fair value of the liability for the 2018 PIPE Warrants during the three months ended March 31, 2020 was recorded as other income (expense) in the condensed consolidated statements of operations.  The Company has calculated the fair value of the 2018 PIPE Warrants using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The following summarizes certain key assumptions used in estimating the fair values.   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div> The Monte Carlo simulation of a geometric Brownian motion model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates. <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Volatility: The Company calculates the estimated volatility rate based on the volatilities of common stock of comparable companies in its industry.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Contractual term: The expected life of the warrants, which is based on the contractual term of the warrants.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Expected dividend yield: The Company has never declared or paid any cash dividends and does not currently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.</td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap">  </td> <td valign="top" style="width:3.4%;white-space:nowrap"> •</td> <td valign="top"> Risk-free rate: The risk-free interest rate is based on the U.S. Treasury rate for similar periods as those of expected volatility.</td></tr></table></div>

Recent Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Recently Adopted Accounting Standards In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement”. The ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company has adopted this ASU at the beginning of 2020. The adoption did not have a material impact on the Company’s condensed consolidated financial statements disclosures. Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12: “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance.  The amendments in this Update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company has not yet assessed the potential impact of adopting ASU 2019-12 on its condensed consolidated financial statements. During the three months ended March 31, 2020, other than ASU 2019-12, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated interim financial statements.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE warrant liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Essentialis purchase price contingency liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock warrant and contingent <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   consideration liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,285</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,285</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE warrant liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE warrant liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Essentialis purchase price contingency liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total common stock warrant and contingent <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   consideration liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,114</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities (dollars in thousands). <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Series C Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.8%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Purchase Price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contingent <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,083</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,024,425</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,822</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,617</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,354</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,938</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiration of Series C Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,083</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of 2017 PIPE Warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,166</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of 2018 PIPE Warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(247</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of contingent liability</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">584</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:27.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,024,425</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,656</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,617</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,107</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,522</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The Company used the following inputs. <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.17</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.52</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

The following summarizes certain key assumptions used in estimating the fair values. <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.10</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.60</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

The following summarizes certain key assumptions used in estimating the fair values. <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contractual term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.33</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.56</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

The components of lease expense during the three months ended March 31, 2019 and 2018 were as follows (in thousands):   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.26%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sublease income</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-of-use assets</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.68%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.26%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total finance lease cost</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.68%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.34%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Stock-based compensation expense was recognized in the condensed consolidated statements of operations as follows (in thousands).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">293</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">207</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">392</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The fair value of each award granted during the three months ended March 31, 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0-6.1</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—  %</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes stock option transactions for the three months ended March 31, 2020 as issued under the 2014 Plan:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price per</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,123,117</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.62</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.87</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled/forfeited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,359</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.11</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084,758</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.66</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.59</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested at March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,220,423</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.65</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.01</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest at March 31, 2020</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084,758</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.66</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.59</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table summarizes restricted stock unit transactions for the three months ended March 31, 2020 as issued under the Plan: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted- <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant-Date Fair Value per Share</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:74.66%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">687,257</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.8%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.83</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units vested</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28,757</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:74.66%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March 31, 2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.8%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.85</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares).   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued to 2010/2012 convertible note <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   holders to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,070</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,070</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,084,758</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,116,107</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding restricted stock units</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658,500</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued to underwriter to purchase common stock</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,500</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A warrants to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485,121</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series C warrants to purchase common stock</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118,083</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series D warrants to purchase common stock</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,540</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">540,540</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017 PIPE warrants</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,024,425</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,024,425</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018 PIPE warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,617</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">513,617</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,940,410</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,916,463</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

15100000

30000000

7656000

1107000

6522000 6522000

15285000

10822000

1354000

5938000 5938000

18114000

118083

6024425

10822000

513617

1354000

5938000

-118083

-3166000

-247000

584000

6024425

7656000

513617

1107000

6522000

0.90

P2M1D

0.0152

8141116

0.74

2.00

1.72

-3200000

7700000

1.05

0.99

P8M12D

P1Y

0.0010

0.0160

10272375

0.05

2.00

1100000

-247000

1.05

0.99

P3Y8M12D

P4Y

0.0033

0.0156

0.00

25000

6368

the Company executed a non-cancellable lease agreement for 6,368 square feet of new space in Redwood City, California, which began in September 2019 and expires in May 2021

2019-09 2021-05

29000

30000

76000

119000

65000

76000 54000

2000

1000

3000 2200000

1.00

1200000 1200000

1690322

0.53

0.47

0 0.10

1.10

P4Y

P5Y

P10Y

190601

99000

41000

293000

207000

392000

248000

464000

P6Y

P6Y1M6D

0.026

0.71

0.00

2123117

38359

2084758

1220423

2084758

4.62

2.11

4.66

6.65

4.66

P7Y10M13D

P7Y7M2D

P7Y3D

P7Y7M2D

1.08

919000

P2Y2M12D

883000

687257

21415

1.00

P4Y

28757

658500

3.83

3.35

3.85

2.18

96000

46000

2400000

P3Y8M12D

27967

0.010

55936

270270

540540

8.75

P5Y 2020-10-15 0.01

102070

24.35

P10Y 2024-11

16500

35.70

P10Y 2024-11

102070

2084758

2116107

658500

16500

485121

118083

540540

6024425

513617

9940410

9916463

350000

EX-101.SCH 7 slno-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Overview link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Going Concern and Management's Plans link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Fair Value of Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Warrant Liabilities link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - CoSense Joint Venture Agreement and Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Net loss per share link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Fair Value of Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Warrant Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Net loss per share (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Going Concern and Management's Plans - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Warrant Liabilities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - CoSense Joint Venture Agreement and Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Transactions (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Net loss per share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Subsequent Events - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 slno-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 slno-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 slno-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Asset acquisition contingent consideration liability noncurrent. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock Shares Outstanding Entity Common Stock Shares Outstanding Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code City Area Code Local Phone Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity Interactive Data Current Entity Interactive Data Current Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] 2017 PIPE warrant liability. 2017 PIPE Warrant Liability [Member] Two Thousand Seventeen P I P E Warrant Liability [Member] 2018 PIPE warrant liability. 2018 PIPE Warrant Liability [Member] Two Thousand Eighteen P I P E Warrant Liability [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Long-term assets Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use assets Operating Lease Right Of Use Asset Finance lease right-of-use assets Finance Lease Right Of Use Asset Intangible assets, net Intangible Assets Net Excluding Goodwill Other long-term assets Other Assets Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued compensation Employee Related Liabilities Current Accrued clinical trial site costs Accrued Clinical Trial Costs Current Operating lease liabilities Operating Lease Liability Current Other current liabilities Other Liabilities Current Total current liabilities Liabilities Current Long-term liabilities Liabilities Noncurrent [Abstract] Warrant liability Derivative Liabilities Noncurrent Contingent liability for Essentialis purchase price Asset Acquisition Contingent Consideration Liability Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 6) Commitments And Contingencies Stockholders’ equity Stockholders Equity [Abstract] Common stock Common Stock Value Additional paid-in-capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Common stock, par value (in dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Asset acquisition contingent consideration change in fair value. Income loss from minority interest investments. Income Statement [Abstract] Operating expenses Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Change in fair value of contingent consideration Asset Acquisition Contingent Consideration Change In Fair Value Total operating expenses Operating Expenses Operating loss Operating Income Loss Other income (expense) Nonoperating Income Expense [Abstract] Change in fair value of warrants liabilities Fair Value Adjustment Of Warrants Loss from minority interest investment Income Loss From Minority Interest Investments Interest income Other Nonoperating Income Expense Total other income (expense) Nonoperating Income Expense Net loss Net Income Loss Net loss per common share, basic and diluted Earnings Per Share Basic And Diluted Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Retained Earnings [Member] Balances at beginning Balances at beginning (shares) Shares Outstanding Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase Decrease In Stockholders Equity Roll Forward Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Issuance of restricted stock units under equity incentive plans Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of restricted stock units under equity incentive plans (shares) Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Net loss Balances at ending Balances at end (shares) Noncash lease expense. Increase decrease in accrued clinical trial site costs. Increase decrease in operating lease liabilities. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Noncash lease expense Noncash Lease Expense Stock-based compensation expense Share Based Compensation Change in fair value of stock warrants Operating loss on minority interest investment Income Loss From Equity Method Investments Change in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses, other current assets and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Due from related party Increase Decrease In Due From Related Parties Accounts payable Increase Decrease In Accounts Payable Accrued compensation Increase Decrease In Employee Related Liabilities Accrued clinical trial site costs Increase Decrease In Accrued Clinical Trial Site Costs Operating lease liabilities Increase Decrease In Operating Lease Liabilities Other liabilities Increase Decrease In Other Operating Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Principal paid on finance lease liabilities Finance Lease Principal Payments Net cash used in financing activities Net Cash Provided By Used In Financing Activities Net decrease in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash and cash equivalents, end of period Accounting Policies [Abstract] Overview Business Description And Basis Of Presentation [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Going Concern and Management's Plans Substantial Doubt About Going Concern [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Warrant Liability Disclosure [Text Block] Text Block [Abstract] Warrant Liabilities Warrant Liability Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Discontinued Operations And Disposal Groups [Abstract] CoSense Joint Venture Agreement and Discontinued Operations Disposal Groups Including Discontinued Operations Disclosure [Text Block] Equity [Abstract] Stockholders' Equity Shareholders Equity And Share Based Payments [Text Block] Earnings Per Share [Abstract] Net loss per share Earnings Per Share [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Use of Estimates Use Of Estimates Recent Accounting Standards New Accounting Pronouncements Policy Policy [Text Block] Summary of Financial Instruments Measured at Fair Value on Recurring Basis Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block] Summary of Changes in Fair Value of Level 3 Financial Instruments Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Series C Warrants [Member] Series C Warrant [Member] Series C Warrants [Member] Fair Value of Convertible Preferred Stock Warrant Liability Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block] Schedule of Components of Lease Expense Lease Cost Table [Text Block] Summary of Stock Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Stock Option Transactions Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Restricted Stock Unit Transactions Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block] Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Cash on hand Cash Net cash used in operating activities Asset acquisition contingent consideration arrangements. Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Schedule Of Significant Accounting Policies [Table] Asset purchase. Asset Purchase Asset Purchase [Axis] Asset purchase. Asset Purchase Asset Purchase [Domain] Essentialis, Inc. Essentialis, Inc. [Member] Essentialis Inc [Member] Contingent Consideration by Type Contingent Consideration By Type [Axis] Contingent Consideration Type Contingent Consideration Type [Domain] Earnout Payments [Member] Earnout Payments [Member] Earnout Payments [Member] Schedule Of Significant Accounting Policies [Line Items] Schedule Of Significant Accounting Policies [Line Items] Maximum potential cash earnout payments Asset Acquisition Contingent Consideration Arrangements Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 [Member] Fair Value Inputs Level1 [Member] Level 2 [Member] Fair Value Inputs Level2 [Member] Level 3 [Member] Fair Value Inputs Level3 [Member] Measurement Frequency Fair Value By Measurement Frequency [Axis] Measurement Frequency Fair Value Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value Measurements Recurring [Member] Liability Class Fair Value By Liability Class [Axis] Fair Value by Liability Class Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain] Derivative Financial Instruments, Liabilities Derivative Financial Instruments Liabilities [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Liabilities Liabilities Fair Value Disclosure [Abstract] Total common stock warrant and contingent consideration liability Liabilities Fair Value Disclosure Expiration of warrants. Fair value measurement with unobservable inputs reconciliation recurring basis liability expiration. Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table] Common Stock Warrant Liability [Member] Common stock warrant liability [Member] Common Stock Warrant Liability [Member] Purchase price contingent liability. Purchase price contingent liability [Member] Purchase Price Contingent Liability [Member] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward Balance at the beginning of period Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Balance at the beginning of period, in shares EX-101.PRE 11 slno-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 3. Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Recent Accounting Standards

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

XML 13 R29.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended			3 Months Ended
	Sep. 30, 2020 USD ($)	Nov. 30, 2019 USD ($)	Jul. 31, 2019 USD ($) ft²	Mar. 31, 2020	Mar. 31, 2019 USD ($)
Commitments and Contingencies [Line Items]
Sublease income					$ 65,000
Redwood City, California [Member]
Commitments and Contingencies [Line Items]
Area of operating lease \| ft²			6,368
Operating lease, description				the Company executed a non-cancellable lease agreement for 6,368 square feet of new space in Redwood City, California, which began in September 2019 and expires in May 2021
Operating lease beginning date			2019-09
Operating lease, expiration			2021-05
Payment to acquire office furniture under operating lease			$ 1
Future minimum commitment under non-cancelable operating lease		$ 29,000
Redwood City, California [Member] \| Forecast [Member]
Commitments and Contingencies [Line Items]
Future minimum commitment under non-cancelable operating lease	$ 30,000
Capnia Inc Joint Venture [Member] \| Redwood City, California [Member]
Commitments and Contingencies [Line Items]
Sublease income					$ 25,000

XML 14 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Summary of Stock Based Compensation Expense

Stock-based compensation expense was recognized in the condensed consolidated statements of operations as follows (in thousands).

	Three Months Ended March 31,
	2020		2019
Research and development	$	99	$	41
General and administrative		293		207
Total	$	392	$	248

Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model

The fair value of each award granted during the three months ended March 31, 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions

Expected life (years)		6.0-6.1
Risk-free interest rate		2.6%
Volatility		71%
Dividend rate		— %

Summary of Stock Option Transactions

The following table summarizes stock option transactions for the three months ended March 31, 2020 as issued under the 2014 Plan:

	Number of Options			Weighted- Average Exercise Price per		Weighted Average Remaining Contractual Term
	Outstanding			Share		(in years)
Balance at December 31, 2019		2,123,117		$	4.62		7.87
Options canceled/forfeited		(38,359	)	$	2.11
Balance at March 31, 2020		2,084,758		$	4.66		7.59
Options vested at March 31, 2020		1,220,423		$	6.65		7.01
Options vested and expected to vest at March 31, 2020		2,084,758		$	4.66		7.59

Summary of Restricted Stock Unit Transactions

The following table summarizes restricted stock unit transactions for the three months ended March 31, 2020 as issued under the Plan:

	Number of Restricted Stock Units			Weighted- Average Grant-Date Fair Value per Share
Outstanding at December 31, 2019		-
Restricted stock units granted		687,257		$	3.83
Restricted stock units vested		(28,757	)	$	3.35
Outstanding at March 31, 2020		658,500		$	3.85

XML 15 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 08, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Registrant Name	SOLENO THERAPEUTICS INC
Entity Central Index Key	0001484565
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock Shares Outstanding		44,710,790
Entity File Number	001-36593
Entity Tax Identification Number	77-0523891
Entity Address, Address Line One	203 Redwood Shores Parkway
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	650
City Area Code	213-8444
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Current Reporting Status	Yes
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SLNO
Security Exchange Name	NASDAQ

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balances at beginning at Dec. 31, 2018	$ 30,413	$ 32	$ 157,413	$ (127,032)
Balances at beginning (shares) at Dec. 31, 2018		31,755,169
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	202		202
Issuance of restricted stock units under equity incentive plans	46		46
Issuance of restricted stock units under equity incentive plans (shares)		21,415
Net loss	(7,030)			(7,030)
Balances at ending at Mar. 31, 2019	23,631	$ 32	157,661	(134,062)
Balances at end (shares) at Mar. 31, 2019		31,776,584
Balances at beginning at Dec. 31, 2019	14,947	$ 45	172,708	(157,806)
Balances at beginning (shares) at Dec. 31, 2019		44,658,054
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	296		296
Issuance of restricted stock units under equity incentive plans	96		96
Issuance of restricted stock units under equity incentive plans (shares)		28,757
Net loss	(5,858)			(5,858)
Balances at ending at Mar. 31, 2020	$ 9,481	$ 45	$ 173,100	$ (163,664)
Balances at end (shares) at Mar. 31, 2020		44,686,811

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R25.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Liabilities
Contingent liability for Essentialis purchase price	$ 6,522	$ 5,938
2017 PIPE Warrant Liability [Member]
Liabilities
Warrant liability	7,656	10,822
2018 PIPE Warrant Liability [Member]
Liabilities
Warrant liability	1,107	1,354
Fair Value, Measurements, Recurring [Member]
Liabilities
Total common stock warrant and contingent consideration liability	15,285	18,114
Fair Value, Measurements, Recurring [Member] \| Derivative Financial Instruments, Liabilities \| 2017 PIPE Warrant Liability [Member]
Liabilities
Warrant liability	7,656	10,822
Fair Value, Measurements, Recurring [Member] \| Derivative Financial Instruments, Liabilities \| 2018 PIPE Warrant Liability [Member]
Liabilities
Warrant liability	1,107	1,354
Essentialis, Inc. [Member] \| Fair Value, Measurements, Recurring [Member]
Liabilities
Contingent liability for Essentialis purchase price	6,522	5,938
Level 3 [Member] \| Fair Value, Measurements, Recurring [Member]
Liabilities
Total common stock warrant and contingent consideration liability	15,285	18,114
Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Derivative Financial Instruments, Liabilities \| 2017 PIPE Warrant Liability [Member]
Liabilities
Warrant liability	7,656	10,822
Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Derivative Financial Instruments, Liabilities \| 2018 PIPE Warrant Liability [Member]
Liabilities
Warrant liability	1,107	1,354
Level 3 [Member] \| Essentialis, Inc. [Member] \| Fair Value, Measurements, Recurring [Member]
Liabilities
Contingent liability for Essentialis purchase price	$ 6,522	$ 5,938

XML 18 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate		2.60%
Volatility		71.00%
Dividend rate	0.00%	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)		6 years
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (years)		6 years 1 month 6 days

XML 19 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Operating lease cost	$ 76	$ 119
Sublease income		(65)
Total operating lease cost	76	$ 54
Amortization of right-of-use assets	2
Interest on lease liabilities	1
Total finance lease cost	$ 3

XML 20 R38.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail)	Apr. 22, 2020 USD ($)
Silicon Valley Bank \| Subsequent Event \| PPP Term Note
Subsequent Event [Line Items]
Principal amount	$ 350,000

XML 21 R13.htm IDEA: XBRL DOCUMENT

CoSense Joint Venture Agreement and Discontinued Operations

3 Months Ended

Mar. 31, 2020

Discontinued Operations And Disposal Groups [Abstract]

CoSense Joint Venture Agreement and Discontinued Operations

Note 7. CoSense Joint Venture Agreement and Discontinued Operations

During October 2018, the Company and OAHL determined and agreed that the cumulative investment made by OAHL exceeded $1.2 million during the quarter ended September 30, 2018. Accordingly, on October 16, 2018, Capnia issued 1,690,322 shares of its common stock to OAHL, representing 53% of its outstanding shares. After the share issuance the Company no longer held a controlling interest in Capnia and resulted in the deconsolidation of Capnia’s financial statements from those of the Company. The remaining 47% investment in Capnia was classified as an equity method investment and was presented as a Minority interest investment in former subsidiary in the condensed consolidated balance sheet. The Company’s share of Capnia’s net losses during the three months ended March 31, 2019 are recorded in the condensed consolidated statements of operations in the line titled “Loss from minority interest investment”. During September 2019, the Company sold its remaining 47% investment in Capnia. Following the transaction, the Company has no interest remaining in Capnia and the previous joint venture agreement with OAHL has been terminated.

XML 22 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a going concern basis in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2020, are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2020. For further information, refer to the financial statements and footnotes included in the Company’s annual financial statements for the fiscal year ended December 31, 2019, which are included in the Company’s annual report on Form 10-K filed with the SEC on March 4, 2020.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Key estimates included in the financial statements include the valuation of deferred income tax assets, the valuation of financial instruments, stock-based compensation, value and life of acquired intangibles, and the valuation of contingent liabilities. The contingent liability represents the fair value of the contingent consideration arising from the Company’s acquisition of Essentialis in 2017. As part of the purchase price, the Company is obligated to make cash earn out payments to Essentialis stockholders up to a maximum of $30 million upon the achievement of certain commercial milestones.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Recently Adopted Accounting Standards In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement”. The ASU modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. The Company has adopted this ASU at the beginning of 2020. The adoption did not have a material impact on the Company’s condensed consolidated financial statements disclosures. Recently Issued Accounting Standards In December 2019, the FASB issued ASU 2019-12: “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendments in this Update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company has not yet assessed the potential impact of adopting ASU 2019-12 on its condensed consolidated financial statements. During the three months ended March 31, 2020, other than ASU 2019-12, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s condensed consolidated interim financial statements.

XML 23 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 134 259 1 false 46 0 false 5 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.soleno.life/20200331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.soleno.life/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.soleno.life/20200331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://www.soleno.life/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) Sheet http://www.soleno.life/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.soleno.life/20200331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 100060 - Disclosure - Overview Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureOverview Overview Notes 7 false false R8.htm 100070 - Disclosure - Going Concern and Management's Plans Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureGoingConcernAndManagementSPlans Going Concern and Management's Plans Notes 8 false false R9.htm 100080 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - Fair Value of Financial Instruments Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 10 false false R11.htm 100100 - Disclosure - Warrant Liabilities Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureWarrantLiabilities Warrant Liabilities Notes 11 false false R12.htm 100110 - Disclosure - Commitments and Contingencies Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 100120 - Disclosure - CoSense Joint Venture Agreement and Discontinued Operations Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureCosenseJointVentureAgreementAndDiscontinuedOperations CoSense Joint Venture Agreement and Discontinued Operations Notes 13 false false R14.htm 100130 - Disclosure - Stockholders' Equity Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 100140 - Disclosure - Net loss per share Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureNetLossPerShare Net loss per share Notes 15 false false R16.htm 100150 - Disclosure - Subsequent Events Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 16 false false R17.htm 100160 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.soleno.life/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies 17 false false R18.htm 100170 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.soleno.life/20200331/taxonomy/role/DisclosureFairValueOfFinancialInstruments 18 false false R19.htm 100180 - Disclosure - Warrant Liabilities (Tables) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureWarrantLiabilitiesTables Warrant Liabilities (Tables) Tables http://www.soleno.life/20200331/taxonomy/role/DisclosureWarrantLiabilities 19 false false R20.htm 100190 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.soleno.life/20200331/taxonomy/role/DisclosureCommitmentsAndContingencies 20 false false R21.htm 100200 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquity 21 false false R22.htm 100210 - Disclosure - Net loss per share (Tables) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureNetLossPerShareTables Net loss per share (Tables) Tables http://www.soleno.life/20200331/taxonomy/role/DisclosureNetLossPerShare 22 false false R23.htm 100220 - Disclosure - Going Concern and Management's Plans - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureGoingConcernAndManagementSPlansAdditionalInformationDetail Going Concern and Management's Plans - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 24 false false R25.htm 100240 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) Details 25 false false R26.htm 100250 - Disclosure - Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfChangesInFairValueOfLevel3FinancialInstrumentsDetail Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) Details 26 false false R27.htm 100260 - Disclosure - Warrant Liabilities - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureWarrantLiabilitiesAdditionalInformationDetail Warrant Liabilities - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureWarrantLiabilitiesFairValueOfConvertiblePreferredStockWarrantLiabilityDetail Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail) Details 28 false false R29.htm 100280 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeaseExpenseDetail Commitments and Contingencies - Schedule of Components of Lease Expense (Detail) Details 30 false false R31.htm 100300 - Disclosure - CoSense Joint Venture Agreement and Discontinued Operations - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureCosenseJointVentureAgreementAndDiscontinuedOperationsAdditionalInformationDetail CoSense Joint Venture Agreement and Discontinued Operations - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetail Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) Details 33 false false R34.htm 100330 - Disclosure - Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquityScheduleOfFairValueOfAwardGrantedUsingBlackScholesOptionPricingModelDetail Stockholders' Equity - Schedule of Fair Value of Award Granted Using Black-Scholes Option Pricing Model (Detail) Details 34 false false R35.htm 100340 - Disclosure - Stockholders' Equity - Summary of Stock Option Transactions (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionTransactionsDetail Stockholders' Equity - Summary of Stock Option Transactions (Detail) Details 35 false false R36.htm 100350 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitTransactionsDetail Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) Details 36 false false R37.htm 100360 - Disclosure - Net loss per share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesOutstandingExcludedFromComputationsOfDilutedWeightedAverageSharesOutstandingDetail Net loss per share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) Details 37 false false R38.htm 100370 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.soleno.life/20200331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 38 false false All Reports Book All Reports slno-20200331.xml slno-20200331.xsd slno-20200331_cal.xml slno-20200331_def.xml slno-20200331_lab.xml slno-20200331_pre.xml http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 24 R35.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Summary of Stock Option Transactions (Detail) - Stock Options [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning balance	2,123,117
Options canceled/forfeited	(38,359)
Ending balance	2,084,758	2,123,117
Options vested at end of period (shares)	1,220,423
Options vested and expected to vest at end of period (shares)	2,084,758
Weighted-Average Exercise Price per Share
Beginning balance (in dollars per share)	$ 4.62
Options canceled/forfeited (in dollars per share)	2.11
Ending balance (in dollars per share)	4.66	$ 4.62
Options vested at end of period (in dollars per share)	6.65
Options vested and expected to vest at end of period (in dollars per share)	$ 4.66
Weighted Average Remaining Contractual Term
Options outstanding at end of period	7 years 7 months 2 days	7 years 10 months 13 days
Options vested at end of period	7 years 3 days
Options vested and expected to vest at end of period	7 years 7 months 2 days

XML 25 R31.htm IDEA: XBRL DOCUMENT

CoSense Joint Venture Agreement and Discontinued Operations - Additional Information (Detail) - Capnia Inc Joint Venture [Member] - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	3 Months Ended
	Oct. 16, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of ownership interest		47.00%	47.00%
OAHL [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Remaining interest		$ 0
OAHL [Member] \| Corporate Joint Venture [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Investment threshold requirement				$ 2,200
Negotiated price per share				$ 1.00
Investment threshold requirement stock issuance			$ 1,200	$ 1,200
Issuance of common stock (shares)	1,690,322
Percentage of ownership interest	53.00%

ZIP 26 0001564590-20-024654-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-024654-xbrl.zip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end

XML 27 R12.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies
3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies
Note 6. Commitments and Contingencies

Facility Leases

The Company’s previous operating lease for its headquarters facility office space in Redwood City, California, terminated in August 2019, along with the related subleases. One of the subleases was with Capnia, of which the Company was a joint owner until September 2019. Sublease income received from Capnia during the three months ended March 31, 2019 was approximately $25,000.

In July 2019, the Company executed a non-cancellable lease agreement for 6,368 square feet of new space in Redwood City, California, which began in September 2019 and expires in May 2021. The lease also provides the Company with the right to use office furniture in the space and allows the purchase of this furniture at the end of the lease term for $1. The lease agreement requires monthly lease payments of approximately $29,000 beginning in November of 2019, with an increase to approximately $30,000 per month in September of 2020. The Company has accounted for the new lease as an operating lease for the office space and a finance lease for the office furniture, based on their relative standalone prices.

The components of lease expense during the three months ended March 31, 2019 and 2018 were as follows (in thousands):

Three Months Ended

March 31,

2020

2019

Operating lease cost:

Operating lease cost

$

76

$

119

Sublease income

—

(65

)

Total operating lease cost

$

76

$

54

Finance lease cost:

Amortization of right-of-use assets

$

2

$

—

Interest on lease liabilities

1

—

Total finance lease cost

$

3

$

—

Contingencies

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.20.1

Subsequent Events
3 Months Ended

Mar. 31, 2020

Subsequent Events [Abstract]

Subsequent Events
Note 10. Subsequent Events

The Company has evaluated its subsequent events from March 31, 2020 through the date these condensed consolidated financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated financial statements other than the item noted below.

PPP Term Note

On April 22, 2020, the Company entered into a $350,000 loan with Silicon Valley Bank (“SVB”) pursuant to the Small Business Administration’s (“SBA”) Paycheck Protection Program ("the PPP"). The loan proceeds were intended to be used for payroll, rent and utilities over the eight- week period following the date of the loan. At the time the Company applied for the PPP loan, it believed in good faith that it met all of the certification requirements for a PPP loan. However, on April 23, 2020, the SBA issued additional guidance with respect to PPP loans. The Company evaluated this new guidance and concluded that currently it may not be able to meet all of the certification requirements. As such, the Company decided to return all of the funds received under the PPP loan (including interest accrued on such funds) to the SBA and on May 6, 2020 the Company instructed SVB to make repayment.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.20.1

Commitments and Contingencies (Tables)
3 Months Ended

Mar. 31, 2020

Commitments And Contingencies Disclosure [Abstract]

Schedule of Components of Lease Expense
The components of lease expense during the three months ended March 31, 2019 and 2018 were as follows (in thousands):

Three Months Ended

March 31,

2020

2019

Operating lease cost:

Operating lease cost

$

76

$

119

Sublease income

—

(65

)

Total operating lease cost

$

76

$

54

Finance lease cost:

Amortization of right-of-use assets

$

2

$

—

Interest on lease liabilities

1

—

Total finance lease cost

$

3

$

—

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R24.htm IDEA: XBRL DOCUMENT v3.20.1

Summary of Significant Accounting Policies - Additional Information (Detail)

Mar. 31, 2020

USD ($)

Essentialis, Inc. [Member] | Earnout Payments [Member]

Schedule Of Significant Accounting Policies [Line Items]

Maximum potential cash earnout payments $ 30,000,000

X

- Definition
Asset acquisition contingent consideration arrangements.
+ References
No definition available.
+ Details

Name: slno_AssetAcquisitionContingentConsiderationArrangements

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Schedule Of Significant Accounting Policies [Line Items]
+ References
No definition available.
+ Details

Name: slno_ScheduleOfSignificantAccountingPoliciesLineItems

Namespace Prefix: slno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: slno_AssetPurchaseAxis=slno_EssentialisIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ContingentConsiderationByTypeAxis=slno_EarnoutPaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 31 R4.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Operating expenses

Research and development $ 6,695 $ 2,760

General and administrative 2,003 2,012

Change in fair value of contingent consideration 584 206

Total operating expenses 9,282 4,978

Operating loss (9,282) (4,978)

Other income (expense)

Change in fair value of warrants liabilities 3,413 (1,919)

Loss from minority interest investment (190)

Interest income 11 57

Total other income (expense) 3,424 (2,052)

Net loss $ (5,858) $ (7,030)

Net loss per common share, basic and diluted $ (0.13) $ (0.22)

Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share 44,679,858 31,756,120

X

- Definition
Asset acquisition contingent consideration change in fair value.
+ References
No definition available.
+ Details

Name: slno_AssetAcquisitionContingentConsiderationChangeInFairValue

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Income loss from minority interest investments.
+ References
No definition available.
+ Details

Name: slno_IncomeLossFromMinorityInterestInvestments

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 32 R28.htm IDEA: XBRL DOCUMENT v3.20.1

Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail)

Mar. 31, 2020

Dec. 31, 2019

Expected Dividend Yield [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 0.00

Series C Warrant [Member] | Volatility [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 0.90

Series C Warrant [Member] | Contractual Term [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement term 2 months 1 day

Series C Warrant [Member] | Risk-free Rate [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 0.0152

2017 PIPE Warrant Liability [Member] | Volatility [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 1.05 0.99

2017 PIPE Warrant Liability [Member] | Contractual Term [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement term 8 months 12 days 1 year

2017 PIPE Warrant Liability [Member] | Risk-free Rate [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 0.0010 0.0160

2018 PIPE Warrant Liability [Member] | Volatility [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 1.05 0.99

2018 PIPE Warrant Liability [Member] | Contractual Term [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement term 3 years 8 months 12 days 4 years

2018 PIPE Warrant Liability [Member] | Risk-free Rate [Member]

Fair Value Measurement Inputs and Valuation Techniques [Line Items]

Measurement input 0.0033 0.0156

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Definition
Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesCWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 33 R8.htm IDEA: XBRL DOCUMENT v3.20.1

Going Concern and Management's Plans
3 Months Ended

Mar. 31, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Going Concern and Management's Plans
Note 2. Going Concern and Management’s Plans

The Company had a net loss of $5.9 million during the three months ended March 31, 2020 and has an accumulated deficit of $163.7 million at March 31, 2020 resulting from having incurred losses since its inception. The Company had $15.1 million of cash on hand at March 31, 2020 and used $5.7 million of cash in its operating activities during the three months ended March 31, 2020. The Company has financed its operations principally through issuances of equity securities.

The accompanying condensed consolidated financial statements have been prepared under the assumption the Company will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

The Company expects to continue incurring losses for the foreseeable future and will be required to raise additional capital to complete its clinical trials, pursue product development initiatives and penetrate markets for the sale of its products. Management believes that the Company will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but the Company’s access to such capital resources is uncertain and is not assured. If the Company is unable to secure additional capital, it may be required to curtail its clinical trials and development of new products and take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s efforts to complete its clinical trials and commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should it be unable to continue as a going concern.

Management believes that the Company does not have sufficient capital resources to sustain operations through at least the next twelve months from the date of this filing. Additionally, in view of the Company’s expectation to incur significant losses for the foreseeable future it will be required to raise additional capital resources in order to fund its operations, although the availability of, and the Company’s access to such resources is not assured. Accordingly, management believes that there is substantial doubt regarding the Company’s ability to continue operating as a going concern within one year from the date of filing these financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 R18.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value of Financial Instruments (Tables)
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Summary of Financial Instruments Measured at Fair Value on Recurring Basis
The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).

Fair Value Measurements at March 31, 2020

Total

Level 1

Level 2

Level 3

Liabilities

2017 PIPE warrant liability

$

7,656

$

—

$

—

$

7,656

2018 PIPE warrant liability

1,107

—

—

1,107

Essentialis purchase price contingency liability

6,522

—

—

6,522

Total common stock warrant and contingent

 consideration liability

$

15,285

$

—

$

—

$

15,285

Fair Value Measurements at December 31, 2019

Total

Level 1

Level 2

Level 3

Liabilities

2017 PIPE warrant liability

$

10,822

$

—

$

—

$

10,822

2018 PIPE warrant liability

1,354

—

—

1,354

Essentialis purchase price contingency liability

5,938

—

—

5,938

Total common stock warrant and contingent

 consideration liability

$

18,114

$

—

$

—

$

18,114

Summary of Changes in Fair Value of Level 3 Financial Instruments
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities (dollars in thousands).

Series C Warrants

2017 PIPE Warrants

2018 PIPE Warrants

Purchase Price

Number of

Warrants

Liability

Number of

Warrants

Liability

Number of

Warrants

Liability

Contingent

Liability

Balance at December 31, 2019

118,083

$

—

6,024,425

$

10,822

513,617

$

1,354

$

5,938

Expiration of Series C Warrants

(118,083

)

—

—

—

—

—

—

Change in value of 2017 PIPE Warrants

—

—

—

(3,166

)

—

—

—

Change in value of 2018 PIPE Warrants

—

—

—

—

—

(247

)

—

Change in value of contingent liability

—

—

—

—

—

—

584

Balance at March 31, 2020

—

$

—

6,024,425

$

7,656

513,617

$

1,107

$

6,522

X

- Definition
Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2C
-URI http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R10.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value of Financial Instruments
3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments
Note 4. Fair Value of Financial Instruments

The carrying value of the Company’s cash, cash equivalents and accounts payable, approximate fair value due to the short-term nature of these items.

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

•

Level I — Unadjusted quoted prices in active markets for identical assets or liabilities;

•

Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

•

Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands).

Fair Value Measurements at March 31, 2020

Total

Level 1

Level 2

Level 3

Liabilities

2017 PIPE warrant liability

$

7,656

$

—

$

—

$

7,656

2018 PIPE warrant liability

1,107

—

—

1,107

Essentialis purchase price contingency liability

6,522

—

—

6,522

Total common stock warrant and contingent

 consideration liability

$

15,285

$

—

$

—

$

15,285

Fair Value Measurements at December 31, 2019

Total

Level 1

Level 2

Level 3

Liabilities

2017 PIPE warrant liability

$

10,822

$

—

$

—

$

10,822

2018 PIPE warrant liability

1,354

—

—

1,354

Essentialis purchase price contingency liability

5,938

—

—

5,938

Total common stock warrant and contingent

 consideration liability

$

18,114

$

—

$

—

$

18,114

The Company’s estimated fair value of the 2017 PIPE Warrants and the 2018 PIPE Warrants was calculated using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation-pricing model requires the input of highly subjective assumptions including the expected stock price volatility, the expected term, the expected dividend yield and the risk-free interest rate. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Company’s analysis of the likelihood of obtaining specified approvals from the Federal Drug Administration as well as reaching cumulative revenue milestones. The Level 3 estimates are based, in part, on subjective assumptions.

During the periods presented, the Company has not changed the manner in which it values liabilities that are measured at fair value using Level 3 inputs. There were no transfers between levels within the hierarchy during the periods presented.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 liabilities (dollars in thousands).

Series C Warrants

2017 PIPE Warrants

2018 PIPE Warrants

Purchase Price

Number of

Warrants

Liability

Number of

Warrants

Liability

Number of

Warrants

Liability

Contingent

Liability

Balance at December 31, 2019

118,083

$

—

6,024,425

$

10,822

513,617

$

1,354

$

5,938

Expiration of Series C Warrants

(118,083

)

—

—

—

—

—

—

Change in value of 2017 PIPE Warrants

—

—

—

(3,166

)

—

—

—

Change in value of 2018 PIPE Warrants

—

—

—

—

—

(247

)

—

Change in value of contingent liability

—

—

—

—

—

—

584

Balance at March 31, 2020

—

$

—

6,024,425

$

7,656

513,617

$

1,107

$

6,522

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R14.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity
3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Stockholders' Equity
Note 8. Stockholders’ Equity

Equity Incentive Plans

The Company has adopted the 2014 Equity Incentive Plan, or the Plan. Under the Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance units or performance shares to employees, directors, advisors, and consultants. Options granted under the Plan may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees, including officers and directors.

The Board of Directors has the authority to determine to whom stock options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. The vesting period is normally monthly over a period of 4 years from the vesting date. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The terms and conditions governing restricted stock units is at the sole discretion of the Board. As of March 31, 2020, a total of 190,601 shares are available for future grant under the Plan.

The Company recognizes stock-based compensation expense related to options and restricted stock units granted to employees, directors and consultants. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the statements of operations for stock-based compensation arrangements during any of the periods presented.

Stock-based compensation expense was recognized in the condensed consolidated statements of operations as follows (in thousands).

Three Months Ended March 31,

2020

2019

Research and development

$

99

$

41

General and administrative

293

207

Total

$

392

$

248

Stock Options

The Company granted options to purchase 464,000 of the Company’s common stock during the three months ended March 31, 2019. There were no options granted during the three months ended March 31, 2020. The fair value of each award granted during the three months ended March 31, 2019 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions.

Expected life (years)

6.0-6.1

Risk-free interest rate

2.6%

Volatility

71%

Dividend rate

— %

The Black-Scholes option-pricing model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates:

•

Expected life: The expected life of stock options represents the average of the contractual term of the options and the weighted-average vesting period, as permitted under the simplified method. The Company does not believe it is able to rely on historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term for use in estimating the fair value-based measurement of stock options. Therefore, it has opted to use the “simplified method” for estimating the expected term of options.

•

Risk-free interest rate: The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected time to liquidity.

•

Volatility: The estimated volatility rate based on the volatilities of common stock of comparable companies in the Company’s industry.

•

Dividend rate: The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.

The following table summarizes stock option transactions for the three months ended March 31, 2020 as issued under the 2014 Plan:

Number of

Options

Weighted-

Average

Exercise

Price per

Weighted

Average

Remaining

Contractual

Term

Outstanding

Share

(in years)

Balance at December 31, 2019

2,123,117

$

4.62

7.87

Options canceled/forfeited

(38,359

)

$

2.11

Balance at March 31, 2020

2,084,758

$

4.66

7.59

Options vested at March 31, 2020

1,220,423

$

6.65

7.01

Options vested and expected to vest at March 31, 2020

2,084,758

$

4.66

7.59

The weighted-average grant date fair value of options granted was and $1.08 per share for the three months ended March 31, 2019. At March 31, 2020 total unrecognized employee stock-based compensation related to stock options was approximately $919,000, which is expected to be recognized over the weighted-average remaining vesting period of 2.2 years. As of March 31, 2020, the outstanding stock options had an intrinsic value of approximately $883,000.

Restricted Stock Units

There were 687,257 and 21,415 restricted stock units granted by the Company during the three months ended March 31, 2020 and March 31, 2019, respectively, to employees and directors. The shares granted to directors were 100% vested on the grant date and represent compensation for past board services. The shares granted to employees typically vest annually over a period of four years. The shares were valued based on the Company’s common stock price on the grant date.

The following table summarizes restricted stock unit transactions for the three months ended March 31, 2020 as issued under the Plan:

Number of

Restricted Stock Units

Weighted-

Average

Grant-Date Fair Value per Share

Outstanding at December 31, 2019

-

Restricted stock units granted

687,257

$

3.83

Restricted stock units vested

(28,757

)

$

3.35

Outstanding at March 31, 2020

658,500

$

3.85

The weighted-average grant-date fair value of all restricted stock units granted during the three months ended March 31, 2020 and March 31, 2019 was $3.83 and $2.18, respectively. The fair value of all restricted stock units vested during the three months ended March 31, 2020 and March 31, 2019 was approximately $96,000 and approximately $46,000, respectively. At March 31, 2020 total unrecognized employee stock-based compensation related to restricted stock units was $2.4 million, which is expected to be recognized over the weighted-average remaining vesting period of 3.7 years.

2014 Employee Stock Purchase Plan

The Company’s board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan, or the ESPP. The ESPP has become effective, and the board of directors will implement commencement of offers thereunder in its discretion. A total of 27,967 shares of the Company’s common stock has been made available for sale under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that the board of directors authorizes commencement, equal to the least of:

•

1.0% of the outstanding shares of the Company’s common stock on the first day of such year;

•

55,936 shares; or

•

such amount as determined by the board of directors.

As of March 31, 2020, there were no purchases by employees under this plan.

Series D Warrants

The Company issued 270,270 Series D Warrants in October 2015, which are exercisable into 540,540 shares of the Company’s common stock, with an exercise price of $8.75 and a term of five years expiring on October 15, 2020. The Company’s Series D Warrants contain standard anti-dilution provisions for stock dividends, stock splits, subdivisions, combinations and similar types of recapitalization events. They also contain a cashless exercise feature that provides for their net share settlement at the option of the holder in the event that there is no effective registration statement covering the continuous offer and sale of the warrants and underlying shares. The Company is required to comply with certain requirements to cause or maintain the effectiveness of a registration statement for the offer and sale of these securities. The Series D Warrant agreement further provides for the payment of liquidated damages at an amount per month equal to 1% of the aggregate VWAP of the shares into which each Series D Warrant is convertible in the event that the Company is unable to maintain the effectiveness of a registration statement as described herein. The Company evaluated the registration payment arrangement stipulated in the terms of this securities agreement and determined that it is probable that the Company will maintain an effective registration statement and has therefore not allocated any portion of the proceeds to the registration payment arrangement. The Series D Warrant agreement specifically provides that under no circumstances will the Company be required to settle any Series D Warrant exercise for cash, whether by net settlement or otherwise.

Accounting Treatment

The Company accounts for the Series D Warrants in accordance with the guidance in ASC 815 Derivatives and Hedging. As indicated above, the Company is not required under any circumstance to settle any Series D Warrant exercise for cash. The Company has therefore classified the value of the Series D Warrants as permanent equity.

Other Common Stock Warrants

As of March 31, 2020, the Company had 102,070 common stock warrants outstanding from the 2010/2012 convertible notes, with an exercise price of $24.35 and a term of 10 years expiring in November 2024. The Company also had 16,500 common stock warrants issued to the underwriter in the Company’s IPO, with an exercise price of $35.70 and a term of 10 years, expiring in November 2024.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R37.htm IDEA: XBRL DOCUMENT v3.20.1

Net loss per share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) - shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 9,940,410 9,916,463

Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 102,070 102,070

Options to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 2,084,758 2,116,107

Outstanding Restricted Stock Units [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 658,500

Warrants Issued to Underwriter to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 16,500 16,500

Series A Warrants to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 485,121

Series C Warrants to Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 118,083

Series D Warrants To Purchase Common Stock [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 540,540 540,540

2017 PIPE Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 6,024,425 6,024,425

2018 PIPE Warrants [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Antidilutive securities excluded from computations of diluted weighted-average shares outstanding 513,617 513,617

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_UnderwriterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesAWarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesCWarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesDWarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity - Summary of Stock Based Compensation Expense (Detail) - Continuing Operations [Member] - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock compensation expense $ 392 $ 248

Research and Development [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock compensation expense 99 41

General and Administrative [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]

Total stock compensation expense $ 293 $ 207

X

- Definition
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R22.htm IDEA: XBRL DOCUMENT v3.20.1

Net loss per share (Tables)
3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding
The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares).

As of March 31,

2020

2019

Warrants issued to 2010/2012 convertible note

 holders to purchase common stock

102,070

102,070

Options to purchase common stock

2,084,758

2,116,107

Outstanding restricted stock units

658,500

—

Warrants issued to underwriter to purchase common stock

16,500

16,500

Series A warrants to purchase common stock

—

485,121

Series C warrants to purchase common stock

—

118,083

Series D warrants to purchase common stock

540,540

540,540

2017 PIPE warrants

6,024,425

6,024,425

2018 PIPE warrants

513,617

513,617

Total

9,940,410

9,916,463

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R2.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2020

Dec. 31, 2019

Current assets

Cash and cash equivalents $ 15,070 $ 20,733

Prepaid expenses and other current assets 572 411

Total current assets 15,642 21,144

Long-term assets

Property and equipment, net 19 22

Operating lease right-of-use assets 332 398

Finance lease right-of-use assets 22 24

Intangible assets, net 16,039 16,525

Other long-term assets 59 59

Total assets 32,113 38,172

Current liabilities

Accounts payable 3,480 1,995

Accrued compensation 338 283

Accrued clinical trial site costs 2,846 1,999

Operating lease liabilities 315 305

Other current liabilities 308 382

Total current liabilities 7,287 4,964

Long-term liabilities

Contingent liability for Essentialis purchase price 6,522 5,938

Other long-term liabilities 60 147

Total liabilities 22,632 23,225

Commitments and contingencies (Note 6)

Stockholders’ equity

Common stock 45 45

Additional paid-in-capital 173,100 172,708

Accumulated deficit (163,664) (157,806)

Total stockholders’ equity 9,481 14,947

Total liabilities and stockholders’ equity 32,113 38,172

2017 PIPE Warrant Liability [Member]

Long-term liabilities

Warrant liability 7,656 10,822

2018 PIPE Warrant Liability [Member]

Long-term liabilities

Warrant liability $ 1,107 $ 1,354

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial services received from vendors, such as accrued contract research organization costs, patient costs, clinical site costs and clinical product cost. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: slno_AccruedClinicalTrialCostsCurrent

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Asset acquisition contingent consideration liability noncurrent.
+ References
No definition available.
+ Details

Name: slno_AssetAcquisitionContingentConsiderationLiabilityNoncurrent

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's right to use underlying asset under operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAsset

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R6.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Cash flows from operating activities:

Net loss $ (5,858) $ (7,030)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 489 489

Noncash lease expense 68 110

Stock-based compensation expense 392 248

Change in fair value of stock warrants (3,413) 1,919

Change in fair value of contingent consideration 584 206

Operating loss on minority interest investment 190

Change in operating assets and liabilities:

Prepaid expenses, other current assets and other assets (161) (74)

Due from related party (8)

Accounts payable 1,485 324

Accrued compensation 55 (92)

Accrued clinical trial site costs 847 188

Operating lease liabilities 10 (117)

Other liabilities (157) (40)

Net cash used in operating activities (5,659) (3,687)

Cash flows from investing activities:

Purchases of property and equipment (10)

Net cash used in investing activities (10)

Cash flows from financing activities:

Principal paid on finance lease liabilities (4)

Net cash used in financing activities (4)

Net decrease in cash and cash equivalents (5,663) (3,697)

Cash and cash equivalents, beginning of period 20,733 23,099

Cash and cash equivalents, end of period $ 15,070 $ 19,402

X

- Definition
Asset acquisition contingent consideration change in fair value.
+ References
No definition available.
+ Details

Name: slno_AssetAcquisitionContingentConsiderationChangeInFairValue

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase decrease in accrued clinical trial site costs.
+ References
No definition available.
+ Details

Name: slno_IncreaseDecreaseInAccruedClinicalTrialSiteCosts

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Increase decrease in operating lease liabilities.
+ References
No definition available.
+ Details

Name: slno_IncreaseDecreaseInOperatingLeaseLiabilities

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Noncash lease expense.
+ References
No definition available.
+ Details

Name: slno_NoncashLeaseExpense

Namespace Prefix: slno_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for principal payment on finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_FinanceLeasePrincipalPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) for proportionate share of equity method investee's income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(12))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(10))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(f))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570
+ Details

Name: us-gaap_IncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in operating liabilities classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 44 R26.htm IDEA: XBRL DOCUMENT v3.20.1

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail)
$ in Thousands
3 Months Ended

Mar. 31, 2020

USD ($)

shares

Purchase price contingent liability [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Balance at the beginning of period $ 5,938

Change in value of liabilities 584

Balance at end of period $ 6,522

Series C Warrant [Member] | Common stock warrant liability [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Balance at the beginning of period, in shares | shares 118,083

Expiration of warrants, in shares | shares (118,083)

2017 PIPE Warrant Liability [Member] | Common stock warrant liability [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Balance at the beginning of period $ 10,822

Balance at the beginning of period, in shares | shares 6,024,425

Change in value of liabilities $ (3,166)

Balance at end of period $ 7,656

Balance at the end of period, in shares | shares 6,024,425

2018 PIPE Warrant Liability [Member] | Common stock warrant liability [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Balance at the beginning of period $ 1,354

Balance at the beginning of period, in shares | shares 513,617

Change in value of liabilities $ (247)

Balance at end of period $ 1,107

Balance at the end of period, in shares | shares 513,617

X

- Definition
Expiration of warrants.
+ References
No definition available.
+ Details

Name: slno_ExpirationOfWarrants

Namespace Prefix: slno_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=slno_PurchasePriceContingentLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesCWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=slno_CommonStockWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R3.htm IDEA: XBRL DOCUMENT v3.20.1

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares

Mar. 31, 2020

Dec. 31, 2019

Statement Of Financial Position [Abstract]

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 44,686,811 44,658,054

Common stock, shares outstanding 44,686,811 44,658,054

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R23.htm IDEA: XBRL DOCUMENT v3.20.1

Going Concern and Management's Plans - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Accounting Policies [Abstract]

Net loss $ (5,858) $ (7,030)

Accumulated deficit (163,664) $ (157,806)

Cash on hand 15,100

Net cash used in operating activities $ (5,659) $ (3,687)

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 47 R27.htm IDEA: XBRL DOCUMENT v3.20.1

Warrant Liabilities - Additional Information (Detail)
3 Months Ended

Mar. 31, 2020

USD ($)

$ / shares

Mar. 31, 2019

USD ($)

Dec. 31, 2019

USD ($)

Dec. 19, 2018

$ / shares

shares

Dec. 15, 2017

$ / shares

shares

Class Of Warrant Or Right [Line Items]

Change in fair value of stock warrants $ (3,413,000) $ 1,919,000

Expected Dividend Yield [Member]

Class Of Warrant Or Right [Line Items]

Measurement input 0.00

Series C Warrant [Member]

Class Of Warrant Or Right [Line Items]

Warrant liability $ 0

2017 PIPE Warrant Liability [Member]

Class Of Warrant Or Right [Line Items]

Warrant liability $ 7,656,000 $ 10,822,000

Number of common stock purchased upon issuance of warrants | shares 8,141,116

Warrant to call common stock | shares 0.74

Exercise price of warrants exercised | $ / shares $ 2.00

Warrant issuance description The 2017 PIPE Warrants were issued on December 15, 2017 in the 2017 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2017 PIPE Offering, and entitle the holder of each of the 8,141,116 units to purchase 0.74 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2017 PIPE Warrants and terminating at the earlier of December 15, 2020 or 30 days following positive Phase III results for the DCCR tablet in PWS.

Change in fair value of stock warrants $ (3,200,000)

Fair value of estimated warrants $ 7,700,000

2017 PIPE Warrant Liability to Purchase Common Stock [Member] | Minimum [Member]

Class Of Warrant Or Right [Line Items]

Exercise price of warrants exercised | $ / shares $ 1.72

2018 PIPE Warrant Liability [Member]

Class Of Warrant Or Right [Line Items]

Warrant liability $ 1,107,000 $ 1,354,000

Number of common stock purchased upon issuance of warrants | shares 10,272,375

Warrant to call common stock | shares 0.05

Exercise price of warrants exercised | $ / shares $ 2.00

Warrant issuance description The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and entitle the holders of each of the 10,272,375 units to purchase 0.05 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2018 PIPE Warrants and terminating on December 21, 2023.

Change in fair value of stock warrants $ (247,000)

Fair value of estimated warrants $ 1,100,000

2018 PIPE Warrant Liability [Member] | Minimum [Member]

Class Of Warrant Or Right [Line Items]

Exercise price of warrants exercised | $ / shares $ 2.00

X

- Definition
Class of Warrant or Right, Exercise Price Description
+ References
No definition available.
+ Details

Name: slno_ClassOfWarrantOrRightExercisePriceDescription

Namespace Prefix: slno_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput

Namespace Prefix: us-gaap_

Data Type: xbrli:decimalItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesCWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R7.htm IDEA: XBRL DOCUMENT v3.20.1

Overview
3 Months Ended

Mar. 31, 2020

Accounting Policies [Abstract]

Overview
Note 1. Overview

Soleno Therapeutics, Inc. (the “Company” or “Soleno”) was incorporated in the State of Delaware on August 25, 1999, and is located in Redwood City, California. The Company initially established its operations as Capnia, a diversified healthcare company that developed and commercialized innovative diagnostics, devices and therapeutics addressing unmet medical needs. During 2017, Soleno received stockholder approval to amend its Amended and Restated Certificate of Incorporation to change its name from “Capnia, Inc.” to “Soleno Therapeutics, Inc.” and merged with Essentialis, Inc. After the merger, the Company’s primary focus has been the development and commercialization of novel therapeutics for the treatment of rare diseases and the Company divested itself of its prior business efforts.

The Company’s lead candidate is Diazoxide Choline Controlled Release tablets, or DCCR, once-daily oral tablets for the treatment of Prader-Willi Syndrome, or PWS. DCCR is currently being evaluated in a Phase III clinical development program. The Phase III study (C601 or DESTINY PWS), a 3-month randomized, double-blind placebo-controlled study, completed enrollment in January 2020 with 127 patients at 29 sites in the US and UK. Patients who complete treatment in DESTINY PWS are eligible to receive DCCR for up to 36 months in C602, an open-label extension study. Top line results from DESTINY PWS are expected in 1H2020. DCCR has orphan designation for the treatment of PWS in the United States, or U.S., as well as in the European Union, or E.U.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 51 R11.htm IDEA: XBRL DOCUMENT v3.20.1

Warrant Liabilities
3 Months Ended

Mar. 31, 2020

Text Block [Abstract]

Warrant Liabilities
Note 5. Warrant Liabilities

The Company has issued multiple warrant series, of which the 2017 PIPE Warrants and the 2018 PIPE Warrants (the “Warrants”) remain outstanding at March 31, 2020 and are considered liabilities pursuant to the guidance established by ASC 815 Derivatives and Hedging.

Accounting Treatment

The Company accounts for the Warrants in accordance with the guidance in ASC 815. As indicated below, the Company may be obligated to settle Warrants in cash. The Company classified the Warrants as long-term liabilities at their fair value and will re-measure the warrants at each balance sheet date until they are exercised or expire. Any change in the fair value is recognized as other income (expense) in the Company’s condensed consolidated statements of operations.

Series C Warrants

As of March 31, 2020, the fair value of the Series C Warrants was zero as the warrants had expired. This balance is consistent with the balance as of December 31, 2019.

The Company calculated the fair value of the Series C Warrants as of December 31, 2019 using a Black-Scholes pricing model. The Black-Scholes pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The Company used the following inputs.

December 31,

2019

Volatility

90

%

Contractual term (years)

0.17

Expected dividend yield

—

%

Risk-free rate

1.52

%

Warrants Issued as Part of the Units in the 2017 PIPE Offering

The 2017 PIPE Warrants were issued on December 15, 2017 in the 2017 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2017 PIPE Offering, and entitle the holder of each of the 8,141,116 units to purchase 0.74 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2017 PIPE Warrants and terminating at the earlier of December 15, 2020 or 30 days following positive Phase III results for the DCCR tablet in PWS.

The exercise price and number of shares of common stock issuable upon exercise of the 2017 PIPE Warrants may be adjusted in certain circumstances, including the event of a stock split, stock dividend, extraordinary dividend, or recapitalization, reorganization, merger or consolidation. However, the exercise price of the 2017 PIPE Warrants will not be reduced below $1.72.

In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology.

As of March 31, 2020, the fair value of the 2017 PIPE Warrants was estimated at $7.7 million. The decrease in the fair value of the liability for the 2017 PIPE Warrants of approximately $3.2 million during the three months ended March 31, 2020 was recorded as other income (expense) in the condensed consolidated statements of operations.

The Company has calculated the fair value of the 2017 PIPE Warrants using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The following summarizes certain key assumptions used in estimating the fair values.

March 31,

2020

December 31,

2019

Volatility

105

%

99

%

Contractual term (years)

0.7

1.0

Expected dividend yield

—

%

—

%

Risk-free rate

0.10

%

1.60

%

Warrants Issued as Part of the Units in the 2018 PIPE Offering

The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and entitle the holders of each of the 10,272,375 units to purchase 0.05 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2018 PIPE Warrants and terminating on December 21, 2023.

The exercise price and number of shares of common stock issuable upon exercise of the 2018 PIPE Warrants may be adjusted in certain circumstances, including the event of a stock split, stock dividend, extraordinary dividend, or recapitalization, reorganization, merger or consolidation. However, the exercise price of the 2018 PIPE Warrants will not be reduced below $2.00.

In the event of a change of control of the Company, the holders of unexercised warrants may present their unexercised warrants to the Company, or its successor, to be purchased by the Company, or its successor, in an amount equal to the per share value determined by the Black Scholes methodology.

As of March 31, 2020, the fair value of the 2018 PIPE Warrants was estimated at $1.1 million. The approximate $247,000 decrease in the fair value of the liability for the 2018 PIPE Warrants during the three months ended March 31, 2020 was recorded as other income (expense) in the condensed consolidated statements of operations.

The Company has calculated the fair value of the 2018 PIPE Warrants using a Monte Carlo simulation of a geometric Brownian motion model. The Monte Carlo simulation pricing model requires the input of highly subjective assumptions including the expected stock price volatility. The following summarizes certain key assumptions used in estimating the fair values.

March 31,

2020

December 31,

2019

Volatility

105

%

99

%

Contractual term (years)

3.7

4.0

Expected dividend yield

—

%

—

%

Risk-free rate

0.33

%

1.56

%

The Monte Carlo simulation of a geometric Brownian motion model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates.

•

Volatility: The Company calculates the estimated volatility rate based on the volatilities of common stock of comparable companies in its industry.

•

Contractual term: The expected life of the warrants, which is based on the contractual term of the warrants.

•

Expected dividend yield: The Company has never declared or paid any cash dividends and does not currently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.

•

Risk-free rate: The risk-free interest rate is based on the U.S. Treasury rate for similar periods as those of expected volatility.

X

- Definition
Warrant Liability Disclosure [Text Block]
+ References
No definition available.
+ Details

Name: slno_WarrantLiabilityDisclosureTextBlock

Namespace Prefix: slno_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R15.htm IDEA: XBRL DOCUMENT v3.20.1

Net loss per share
3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Net loss per share
Note 9. Net loss per share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common stock actually outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock outstanding and dilutive potential common stock that would be issued upon the exercise of common stock warrants and options. For the three months ended March 31, 2020 and 2019, the effect of issuing the potential common stock is anti-dilutive due to the net losses in those periods and the number of shares used to compute basic and diluted earnings per share are the same in each of those periods.

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares).

As of March 31,

2020

2019

Warrants issued to 2010/2012 convertible note

 holders to purchase common stock

102,070

102,070

Options to purchase common stock

2,084,758

2,116,107

Outstanding restricted stock units

658,500

—

Warrants issued to underwriter to purchase common stock

16,500

16,500

Series A warrants to purchase common stock

—

485,121

Series C warrants to purchase common stock

—

118,083

Series D warrants to purchase common stock

540,540

540,540

2017 PIPE warrants

6,024,425

6,024,425

2018 PIPE warrants

513,617

513,617

Total

9,940,410

9,916,463

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R19.htm IDEA: XBRL DOCUMENT v3.20.1

Warrant Liabilities (Tables)
3 Months Ended

Mar. 31, 2020

Series C Warrant [Member]

Fair Value of Convertible Preferred Stock Warrant Liability The Company used the following inputs.

December 31,

2019

Volatility

90

%

Contractual term (years)

0.17

Expected dividend yield

—

%

Risk-free rate

1.52

%

2017 PIPE Warrant Liability [Member]

Fair Value of Convertible Preferred Stock Warrant Liability The following summarizes certain key assumptions used in estimating the fair values.

March 31,

2020

December 31,

2019

Volatility

105

%

99

%

Contractual term (years)

0.7

1.0

Expected dividend yield

—

%

—

%

Risk-free rate

0.10

%

1.60

%

2018 PIPE Warrant Liability [Member]

Fair Value of Convertible Preferred Stock Warrant Liability The following summarizes certain key assumptions used in estimating the fair values.

March 31,

2020

December 31,

2019

Volatility

105

%

99

%

Contractual term (years)

3.7

4.0

Expected dividend yield

—

%

—

%

Risk-free rate

0.33

%

1.56

%

X

- Definition
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesCWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandSeventeenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_TwoThousandEighteenPIPEWarrantLiabilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 54 R36.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity - Summary of Restricted Stock Unit Transactions (Detail) - Restricted Stock Units [Member] - $ / shares
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]

Restricted stock units granted 687,257 21,415

Restricted stock units vested (28,757)

Ending balance 658,500

Weighted-average grant date fair value

Restricted stock units granted (in dollars per share) $ 3.83 $ 2.18

Restricted stock units vested (in dollars per share) 3.35

Ending balance (in dollars per share) $ 3.85

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 55 R32.htm IDEA: XBRL DOCUMENT v3.20.1

Stockholders' Equity - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended

Oct. 31, 2015

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected dividend yield 0.00% 0.00%

Weighted average grant date fair value per option granted (in dollars per share) $ 1.08

Stock options outstanding, intrinsic value $ 883,000

Number of shares available for issuance under the plan on the first day of each year 44,686,811 44,658,054

Series D Warrants [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Warrants outstanding (in shares) 270,270

Number of common stock purchased upon issuance of warrants 540,540

Exercise price of warrants (in dollars per share) $ 8.75

Warrants term 5 years

Warrants expiration date Oct. 15, 2020

Liquidated damages amount percent of VWAP (percent) 1.00%

Warrants to Purchase Stock [Member] | 2010 and 2012 Convertible Promissory Notes [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Warrants outstanding (in shares) 102,070

Exercise price of warrants (in dollars per share) $ 24.35

Warrants term 10 years

Warrants expiration period 2024-11

Underwriter [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Warrants outstanding (in shares) 16,500

Exercise price of warrants (in dollars per share) $ 35.70

Warrants term 10 years

Warrants expiration period 2024-11

Employee Stock Purchase Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of shares available for grant 27,967

Percentage of outstanding stock maximum 1.00%

Number of shares available for issuance under the plan on the first day of each year 55,936

Minimum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Ownership interest of voting rights of all classes of stock (percent) 10.00%

Stock Options [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period 4 years

Number of shares available for grant 190,601

Income tax benefits recognized from stock-based compensation $ 0 $ 0

Number of options granted 0 464,000

Future stock-based compensation for unvested employee options granted and outstanding $ 919,000

Future stock-based compensation, requisite service period 2 years 2 months 12 days

Stock Options [Member] | Minimum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Percentage of fair market value 110.00%

Stock Options [Member] | Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Contractual term of option 10 years

ISOs [Member] | Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Contractual term of option 5 years

Restricted Stock Units [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period 4 years

Future stock-based compensation for unvested employee options granted and outstanding $ 2,400,000

Stock units granted 687,257 21,415

Vesting percentage 100.00%

Weighted average grant-date fair value of all restricted stock units granted $ 3.83 $ 2.18

Fair value of restricted stock units vested $ 96,000 $ 46,000

Weighted average remaining vesting period 3 years 8 months 12 days

X

- Definition
Class Of Warrant Or Right, Warrant Term
+ References
No definition available.
+ Details

Name: slno_ClassOfWarrantOrRightWarrantTerm

Namespace Prefix: slno_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or right warrants expiration date.
+ References
No definition available.
+ Details

Name: slno_ClassOfWarrantOrRightWarrantsExpirationDate

Namespace Prefix: slno_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or right warrants expiration month and year.
+ References
No definition available.
+ Details

Name: slno_ClassOfWarrantOrRightWarrantsExpirationMonthAndYear

Namespace Prefix: slno_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of Warrant Or Right, Liquidated Damages Amount, Percent of Volume Weighted Average Price
+ References
No definition available.
+ Details

Name: slno_ClassofWarrantOrRightLiquidatedDamagesAmountPercentofVolumeWeightedAveragePrice

Namespace Prefix: slno_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Ownership interest, percentage of voting rights of stock.
+ References
No definition available.
+ Details

Name: slno_OwnershipInterestPercentageofVotingRightsofStock

Namespace Prefix: slno_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cost to be recognized for option under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of tax benefit for recognition of expense of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of vesting of award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Purchase price of common stock expressed as a percentage of its fair value.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_SeriesDWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_WarrantsToPurchaseCommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=slno_TwoThousandAndTenAndTwoThousandAndTwelveConvertiblePromissoryNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=slno_UnderwriterMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=slno_IncentiveStockOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Summary of Significant Accounting Policies - Additional Information (Detail)	Mar. 31, 2020 USD ($)
Essentialis, Inc. [Member] \| Earnout Payments [Member]
Schedule Of Significant Accounting Policies [Line Items]
Maximum potential cash earnout payments	$ 30,000,000

Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses
Research and development	$ 6,695	$ 2,760
General and administrative	2,003	2,012
Change in fair value of contingent consideration	584	206
Total operating expenses	9,282	4,978
Operating loss	(9,282)	(4,978)
Other income (expense)
Change in fair value of warrants liabilities	3,413	(1,919)
Loss from minority interest investment		(190)
Interest income	11	57
Total other income (expense)	3,424	(2,052)
Net loss	$ (5,858)	$ (7,030)
Net loss per common share, basic and diluted	$ (0.13)	$ (0.22)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	44,679,858	31,756,120

Warrant Liabilities - Fair Value of Convertible Preferred Stock Warrant Liability (Detail)	Mar. 31, 2020	Dec. 31, 2019
Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.00
Series C Warrant [Member] \| Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.90
Series C Warrant [Member] \| Contractual Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement term		2 months 1 day
Series C Warrant [Member] \| Risk-free Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.0152
2017 PIPE Warrant Liability [Member] \| Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	1.05	0.99
2017 PIPE Warrant Liability [Member] \| Contractual Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement term	8 months 12 days	1 year
2017 PIPE Warrant Liability [Member] \| Risk-free Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.0010	0.0160
2018 PIPE Warrant Liability [Member] \| Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	1.05	0.99
2018 PIPE Warrant Liability [Member] \| Contractual Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement term	3 years 8 months 12 days	4 years
2018 PIPE Warrant Liability [Member] \| Risk-free Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.0033	0.0156

Net loss per share - Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	9,940,410	9,916,463
Warrants Issued to 2010/2012 Convertible Note Holders to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	102,070	102,070
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	2,084,758	2,116,107
Outstanding Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	658,500
Warrants Issued to Underwriter to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	16,500	16,500
Series A Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding		485,121
Series C Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding		118,083
Series D Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	540,540	540,540
2017 PIPE Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	6,024,425	6,024,425
2018 PIPE Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computations of diluted weighted-average shares outstanding	513,617	513,617

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 15,070	$ 20,733
Prepaid expenses and other current assets	572	411
Total current assets	15,642	21,144
Long-term assets
Property and equipment, net	19	22
Operating lease right-of-use assets	332	398
Finance lease right-of-use assets	22	24
Intangible assets, net	16,039	16,525
Other long-term assets	59	59
Total assets	32,113	38,172
Current liabilities
Accounts payable	3,480	1,995
Accrued compensation	338	283
Accrued clinical trial site costs	2,846	1,999
Operating lease liabilities	315	305
Other current liabilities	308	382
Total current liabilities	7,287	4,964
Long-term liabilities
Contingent liability for Essentialis purchase price	6,522	5,938
Other long-term liabilities	60	147
Total liabilities	22,632	23,225
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock	45	45
Additional paid-in-capital	173,100	172,708
Accumulated deficit	(163,664)	(157,806)
Total stockholders’ equity	9,481	14,947
Total liabilities and stockholders’ equity	32,113	38,172
2017 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	7,656	10,822
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 1,107	$ 1,354

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net loss	$ (5,858)	$ (7,030)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	489	489
Noncash lease expense	68	110
Stock-based compensation expense	392	248
Change in fair value of stock warrants	(3,413)	1,919
Change in fair value of contingent consideration	584	206
Operating loss on minority interest investment		190
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	(161)	(74)
Due from related party		(8)
Accounts payable	1,485	324
Accrued compensation	55	(92)
Accrued clinical trial site costs	847	188
Operating lease liabilities	10	(117)
Other liabilities	(157)	(40)
Net cash used in operating activities	(5,659)	(3,687)
Cash flows from investing activities:
Purchases of property and equipment		(10)
Net cash used in investing activities		(10)
Cash flows from financing activities:
Principal paid on finance lease liabilities	(4)
Net cash used in financing activities	(4)
Net decrease in cash and cash equivalents	(5,663)	(3,697)
Cash and cash equivalents, beginning of period	20,733	23,099
Cash and cash equivalents, end of period	$ 15,070	$ 19,402

Fair Value of Financial Instruments - Summary of Changes in Fair Value of Level 3 Financial Instruments (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($) shares
Purchase price contingent liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at the beginning of period	$ 5,938
Change in value of liabilities	584
Balance at end of period	$ 6,522
Series C Warrant [Member] \| Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at the beginning of period, in shares \| shares	118,083
Expiration of warrants, in shares \| shares	(118,083)
2017 PIPE Warrant Liability [Member] \| Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at the beginning of period	$ 10,822
Balance at the beginning of period, in shares \| shares	6,024,425
Change in value of liabilities	$ (3,166)
Balance at end of period	$ 7,656
Balance at the end of period, in shares \| shares	6,024,425
2018 PIPE Warrant Liability [Member] \| Common stock warrant liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at the beginning of period	$ 1,354
Balance at the beginning of period, in shares \| shares	513,617
Change in value of liabilities	$ (247)
Balance at end of period	$ 1,107
Balance at the end of period, in shares \| shares	513,617

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	44,686,811	44,658,054
Common stock, shares outstanding	44,686,811	44,658,054

Warrant Liabilities - Additional Information (Detail)	3 Months Ended
Warrant Liabilities - Additional Information (Detail)	Mar. 31, 2020 USD ($) $ / shares	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Dec. 19, 2018 $ / shares shares	Dec. 15, 2017 $ / shares shares
Class Of Warrant Or Right [Line Items]
Change in fair value of stock warrants	$ (3,413,000)	$ 1,919,000
Expected Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Measurement input	0.00
Series C Warrant [Member]
Class Of Warrant Or Right [Line Items]
Warrant liability	$ 0
2017 PIPE Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Warrant liability	$ 7,656,000		$ 10,822,000
Number of common stock purchased upon issuance of warrants \| shares					8,141,116
Warrant to call common stock \| shares					0.74
Exercise price of warrants exercised \| $ / shares					$ 2.00
Warrant issuance description	The 2017 PIPE Warrants were issued on December 15, 2017 in the 2017 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2017 PIPE Offering, and entitle the holder of each of the 8,141,116 units to purchase 0.74 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2017 PIPE Warrants and terminating at the earlier of December 15, 2020 or 30 days following positive Phase III results for the DCCR tablet in PWS.
Change in fair value of stock warrants	$ (3,200,000)
Fair value of estimated warrants	$ 7,700,000
2017 PIPE Warrant Liability to Purchase Common Stock [Member] \| Minimum [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants exercised \| $ / shares	$ 1.72
2018 PIPE Warrant Liability [Member]
Class Of Warrant Or Right [Line Items]
Warrant liability	$ 1,107,000		$ 1,354,000
Number of common stock purchased upon issuance of warrants \| shares				10,272,375
Warrant to call common stock \| shares				0.05
Exercise price of warrants exercised \| $ / shares				$ 2.00
Warrant issuance description	The 2018 PIPE Warrants were issued on December 19, 2018 in the 2018 PIPE Offering, pursuant to a Warrant Agreement with each of the investors in the 2018 PIPE Offering, and entitle the holders of each of the 10,272,375 units to purchase 0.05 shares of the Company’s common stock at an exercise price equal to $2.00 per share, subject to adjustment as discussed below, at any time commencing upon issuance of the 2018 PIPE Warrants and terminating on December 21, 2023.
Change in fair value of stock warrants	$ (247,000)
Fair value of estimated warrants	$ 1,100,000
2018 PIPE Warrant Liability [Member] \| Minimum [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants exercised \| $ / shares	$ 2.00

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2015	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield		0.00%	0.00%
Weighted average grant date fair value per option granted (in dollars per share)			$ 1.08
Stock options outstanding, intrinsic value		$ 883,000
Number of shares available for issuance under the plan on the first day of each year		44,686,811		44,658,054
Series D Warrants [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants outstanding (in shares)	270,270
Number of common stock purchased upon issuance of warrants	540,540
Exercise price of warrants (in dollars per share)	$ 8.75
Warrants term	5 years
Warrants expiration date	Oct. 15, 2020
Liquidated damages amount percent of VWAP (percent)	1.00%
Warrants to Purchase Stock [Member] \| 2010 and 2012 Convertible Promissory Notes [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants outstanding (in shares)		102,070
Exercise price of warrants (in dollars per share)		$ 24.35
Warrants term		10 years
Warrants expiration period		2024-11
Underwriter [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants outstanding (in shares)		16,500
Exercise price of warrants (in dollars per share)		$ 35.70
Warrants term		10 years
Warrants expiration period		2024-11
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant		27,967
Percentage of outstanding stock maximum		1.00%
Number of shares available for issuance under the plan on the first day of each year		55,936
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ownership interest of voting rights of all classes of stock (percent)		10.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Number of shares available for grant		190,601
Income tax benefits recognized from stock-based compensation		$ 0	$ 0
Number of options granted		0	464,000
Future stock-based compensation for unvested employee options granted and outstanding		$ 919,000
Future stock-based compensation, requisite service period		2 years 2 months 12 days
Stock Options [Member] \| Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of fair market value		110.00%
Stock Options [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual term of option		10 years
ISOs [Member] \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual term of option		5 years
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period		4 years
Future stock-based compensation for unvested employee options granted and outstanding		$ 2,400,000
Stock units granted		687,257	21,415
Vesting percentage		100.00%
Weighted average grant-date fair value of all restricted stock units granted		$ 3.83	$ 2.18
Fair value of restricted stock units vested		$ 96,000	$ 46,000
Weighted average remaining vesting period		3 years 8 months 12 days